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Background: The objectives of this study were to first understand whether a dialysis center’s 
ownership status modified the association between informing end-stage renal disease (ESRD) 
patients about transplantation options and patients’ transplantation status; and second, to 
understand whether Medicare’s Prospective Payment System (PPS) implementation affected 
the cost of care for ESRD patients from Medicare’s perspective.  
Method: This study used the United States Renal Data System (USRDS) data containing 
information on all ESRD patients in the US, linked to Medicare claims. To address the first 
objective, a multi-level analysis using mixed effect multinomial logistic regression model was 
conducted with patients aged 18 to 64, having an ESRD onset during 2006 to 2016. To address 
the second objective, an interrupted time series analysis (ITSA) was used to estimate the effect 
of Medicare’s PPS implementation on cost of care from Medicare’s perspective. The second 
aim examined patients 18 years and above with ESRD onset from 2005 to 2015. Total cost 
was further categorized into total outpatient, outpatient dialysis, outpatient non-dialysis, and 




Results: The study showed that informing patients about transplantation options was 
associated with increased odds of enrolling in kidney transplant wait list (WL) or receiving a 
live donor kidney transplant (LDKT) at both for-profit and non-profit dialysis centers. 
However, this effect was less pronounced at for-profit as compared with non-profit dialysis 
centers (Non-profit dialysis centers: Enrolling in WL OR: 2.23 [95% CI, 2.07-2.40] and 
Receiving an LDKT OR: 3.35 [95% CI, 2.65-4.25]; For-profit dialysis centers: Enrolling in 
WL OR: 1.73 [95% CI, 1.66-1.79] and Receiving an LDKT OR: 2.35 [95% CI, 2.08-2.66]). 
The results also showed that the odds of informing patients was higher for for-profit as 
compared with non-profit dialysis centers, and characteristics of patients informed were similar 
between for-profit and non-profit dialysis centers.  
With respect to costs, the study showed that PPS was significantly associated with decreased 
total cost; total cost remained steady before PPS, but cost declined over time after PPS (-0.88% 
[95% CI: (-0.96, -0.79)]). However, the effect of the PPS was not the same across cost 
categories. Although, total outpatient and outpatient dialysis costs were decreasing over time 
before PPS, these cost categories significantly increased immediately after PPS but continued 
to decline afterward. Outpatient non-dialysis cost was steady before PPS, and after a significant 
decline after PPS, continued to increase over time. Inpatient costs, which were increasing 
before PPS, had an immediate decline after PPS and showed a declining pattern over time after 
PPS. Conclusion:  The first part of the study found that the beneficial effect of informing 
patients on transplantation status differs by the ownership status of the informing facility. 
Information provided by for-profit dialysis centers was less effective and potentially lower 




developing guidelines to standardize transplantation information provided, in order to ensure 
similar informational quality across centers. The study also found that the PPS was associated 
with decreasing total cost of care, however, the effect was not the same for all cost 
subcategories. Nevertheless, PPS seems to have achieved the cost containment goal that it set 
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End-Stage Renal Disease (ESRD) occurs when kidneys fail to effectively filter waste 
products from blood, leading to physiological toxicity and consequent morbidity and 
mortality.1 Prevalence and incidence of ESRD is increasing worldwide,  and the US is no 
exception. Prevalence of ESRD in the US has been increasing at a stable rate since 1996 and  
has more than doubled since 1996.2 In 2017, 124,500 patients developed ESRD resulting in 
746,557 prevalent cases of ESRD at the end of 2017 in the US.2 
Treatment options for ESRD patients are hemodialysis, peritoneal dialysis, or kidney 
transplantation (KT). Hemodialysis involves using a dialysis machine outside the body to 
simulate the kidneys’ function of filtering blood. Peritoneal dialysis is a process in which the 
abdomen is filled with a fluid called dialysate, the abdominal lining (the peritoneum) acts as 
a filter and filters waste into the dialysate, and the dialysate is drained away with the waste 
at the end of the process. In transplantation a new kidney replaces the failed kidneys.3 
Each option has advantages and disadvantages. Hemodialysis facilities are widely available 
in the US; however, patients need to travel to the dialysis centers and receive dialysis on site. 
Hemodialysis also requires a strict diet and fluid limit. Compared with peritoneal dialysis 
patients, hemodialysis patients need to consume more medications and therefore possibly 
spend more money on medications. Hemodialysis also has a home hemodialysis option, 
which can be used at home to reduce difficulties of scheduling and traveling. Patients can 
have more frequent dialysis during the week and probably have a more normal diet in case 





dialysis fluid should be changed every day. Peritoneal dialysis requires fewer diet and fluid 
restrictions than hemodialysis.4  
In case of kidney transplantation, because a transplanted kidney works like a normal kidney, 
patients do not need to continue dialysis, and they can also have a more normal diet. Patients 
who receive a transplant have a higher chance of living longer compared with other treatment 
options. However, the process of KT is complex and requires a major surgery. There are long 
waiting lines for a deceased donor, or patients need to be fortuitous to find a live kidney 
donor. After the transplantation, there is a chance that the body would reject the new kidney, 
so patients must take immunosuppressants to increase the chances of the body accepting  the 
new kidney. Immunosuppressants may cause additional complications.4 
For most ESRD patients, KT remains the best renal replacement practice.5 Studies have 
shown that transplantation has better outcomes than dialysis, with better mortality rates and 
long-term health outcomes associated with transplantation. KT recipients have lower risk of 
cardiovascular events, and they have better quality of life.6 Long-term mortality rates are 
about 68% lower for transplant recipients compared to non-recipients on prolonged dialysis. 
Survival rate after KT is significantly and negatively related to time on dialysis.7 However, 
considering the benefits of KT, only 14% of ESRD patients chose a transplantation option by 
either enrolling in the wait list (WL) or receiving a live donor kidney transplant (LDKT), 
within one year of ESRD onset.8 
Dialysis is a costly and time-consuming treatment process. Most ESRD patients are eligible 
to enroll through Medicare. Considering the growing number of patients requiring ESRD and 





While Medicare’s ESRD population accounts for less than 1% of its total population, it has 
accounted for about 7% of overall Medicare spending in recent years.8 Medicare continues 
to apply new policies to reduce its expenditure by lowering its cost per person per year and 
increasing number of transplantations.  
KT improves patient survival and quality of life, and it saves a significant amount of money 
for Medicare. The first section of this research focuses on differences in effect of informing 
patients about transplantation options on their transplantation status between for-profit and 
non-profit dialysis centers. In 2005, the Centers for Medicare and Medicaid Services (CMS) 
released a new version of Medical Evidence Form-2728 to emphasize the importance of 
transplantation. This form requires dialysis centers to indicate whether each patient was 
informed about KT; if the patient was not informed, the dialysis center must indicate why. 
Even though this form promotes KT education to assist the patients to make informed 
decisions, there is no standardized education about KT for ESRD patients.  
The rate of informing patients about KT options, enrolling on the WL, and receiving LDKT 
differs among dialysis centers. A lower rate of enrolling on WL and LDKT among for-profit 
dialysis centers compared with non-profit dialysis centers has been documented in the 
literature.6,9–11 The first part of this study explores whether the association between informing 
patients about KT options and patient transplantation status within one year after being 
informed depended upon receipt of services at a for-profit versus a non-profit dialysis center. 
Patients can have one of the following statuses during the first year after being informed:  
(a) Deciding to enroll in the WL (WL enrolled) 





(c) Remaining on dialysis (reference category) 
The second part of this study focused on Medicare’s policy change in reimbursing dialysis 
centers. Medicare coverage for ESRD patients began in 1973, when about 16,000 patients 
required regular dialysis. In 2017, ESRD prevalence in the US was 746,557, a 2.5% increase 
over 2016. Medicare expenditures increased by 1.3% in 2017 compared with 2016. In 2017 
Medicare’s fee-for-service ESRD program cost about $36 billion, which accounts for 7.2% 
of the overall Medicare payment for claims.8 Medicare has implemented various policies to 
contain the growing cost. The most recent change in reimbursement policy was implemented 
in January 2011 as a result of the Medicare Improvements for Patients and Providers Act 
(MIPPA) of 2008. MIPPA mandates reimbursement reform to reduce expenditures, which 
led CMS to release the final ruling for implementation of the ESRD Prospective Payment 
System (PPS)  or bundled payment in July 2010, effective from January 2011.12–14 In this 
payment system, Medicare reimburses dialysis centers with a fixed amount of $230 per 
dialysis treatment per patient. This includes cost of dialysis, all injectable and equivalent oral 
medications, and any dialysis-related tests. Bundled payment systems provide incentives to 
use less costly treatments.  
To prevent any possible inadequate treatment, The Quality Incentive Program was started in 
2012 to ensure that dialysis centers meet certain criteria in controlling patients’ average 
hemoglobin and urea reduction levels.15 If a dialysis centers fails to meet these criteria, 
Medicare will deduct penalties from the reimbursement.  
Early research on the effect of the new reimbursement policy shows that utilization of less 





influenced other service types as well, in addition to adverse effects and cost shifting. For 
example, increased inpatient and emergency department blood transfusions imply cost 
shifting from dialysis centers to hospitals and emergency centers. This study aimed at 
exploring changes in Medicare’s payments for dialysis and non-dialysis services. Cost 
categories of interest were total cost of care, total outpatient cost, outpatient dialysis cost, 
outpatient non-dialysis cost, and inpatient cost among new ESRD population after the policy 
implementation. 
Part 1: Aim 1 
KT Education and Transplantation Status 
For most ESRD patients, transplantation is the best renal replacement practice.5 Patients 
might receive KT if they enroll on the WL or they receive an LDKT. The number of patients 
enrolled on the WL has increased over time. In 2017, there were more than 75,000 in the 
WL.8  
Despite the high demand for a  healthy kidney, the gap between the supply and demand has 
increased every year. The median time wait time for a deceased KT was more than 5 years 
in 2017.8  The total number of transplantations performed by year has increased over time; 
the increase is mostly due to increases in deceased KT, as LDKT has been fairly steady during 
the last 5 years. In 2017, 20,945 transplant surgeries were performed.8  
The new version of the CMS Medical Evidence Form-2728, released in 2005, includes a 
query about whether a patient has been informed about KT. If the patient was not informed, 





“Unsuitable due to age,” “Psychologically unfit,” “Patient declines information,” “Patient has 
not been assessed,” and “Other.” 16  
L. M. Kucirkaa et al. used Form-2728 data from 2005 to 2007 and showed that among 
236,079 patients who developed ESRD during study period, 30.1% were not informed about 
KT options. Among these, 42% were not assessed, 30.4% were medically unfit, and 16.9% 
were reported to be unsuitable due to age. They also showed that patients who are not 
informed about KT options have a 53% lower rate of enrollment on WL or receiving an 
LDKT17  
Unequal Provision of KT Education 
The rate of enrolling on the WL and receipt of LDKT differs among dialysis centers; the rate 
is significantly lower for for-profit dialysis centers than for non-profit dialysis centers.6,9–11 
Literature shows that lower likelihood of being placed on a WL for patients treated in for-
profit dialysis centers remains significant after controlling for possible confounders such as 
socioeconomic, demographic, and geographic factors.6,10,18 
Past studies show that more intensive education such as one-on-one discussions, spending 
sufficient time on patient education, and involving patient’s family members and social 
network in the process of transplant education have the potential to influence a patient’s 
decision on transplant and increased LDKT inquiries, completed transplant evaluation, and 
even receiving an LDKT.19–25 For example, Rodrigue et al showed that an intervention to 
involve family members and friends in the transplant education process was successful in 
increasing living donor inquiries, living donor evaluations, and even LDKT among the 





evaluations and LDKT, but not for living donor inquiries.19,20 The results show that high 
quality education has potential to not only increase transplantation but also to reduce the 
racial disparities.  
Waterman et al. in a study on Heartland Kidney Network (Iowa, Kansas, Missouri, and 
Nebraska) from 2009 to 2011, showed a high variation in number of KT education practices 
dialysis centers use. Educational practices such as verbal recommendations to be evaluated 
for KT, referral of patients to an educational program, the opportunity to talk to a kidney 
recipient, detailed discussions about the risks and advantages of KT, and eight other practices 
were studied among dialysis centers. The result of their study indicates that dialysis centers 
that have higher rate of patients enrolled on WL use multiple transplant education practices.26 
This research included a survey on the knowledge of transplantation among educators, 
predominantly dialysis nurses and social workers. On average educators were able to answer 
only 50% of the questions correctly. Educators who reported low level of transplant 
knowledge were more likely to offer lower quality education such as verbal recommendation 
and referral to external transplant education programs. Only 18% of educators have reported 
detailed discussion about KT options with ESRD patients.26 
Balhara et al. surveyed 906 nephrologists practicing in the United States and concluded that 
most nephrologists believe that ideal time for educating patients is more than 20 minutes; 
however, most nephrologists spend less time, especially in for-profit dialysis centers. They 
argue that unequal provision of education might partially explain documented lower rate of 





Public Health Significance 
KT is the best renal replacement practice for most of the ESRD patients.5 It reduces mortality 
risk and improves quality of life.6,7 Because KT patients do not need dialysis anymore (unless 
the KT fails), this treatment option saves a significant amount of money from the Medicare’s 
perspective. In 2017, the per-person-per-year (PPPY) cost for KT patients was $35,817. 
However, the PPPY for dialysis patients was significantly higher ($91,795 for hemodialysis 
and $78,159 for peritoneal dialysis).8 The benefits of increasing the transplant rate for ESRD 
patients include lower mortality rate, better quality of life, and financial savings. 
Educating ESRD patients about KT increases the likelihood of enrollment in the WL and 
receiving an LDKT.17 Previous studies show the positive association between educating 
patients about KT options and patient’s KT status. The use of more knowledgeable educators 
and multiple educational practices were associated with a higher rate of waitlisted patients in 
dialysis centers at Heartland Kidney Network.26 Research also shows there is a significant 
variation in how dialysis centers provide transplant education, which leads to variations in 
the rate of enrollment in the WL and rate of receiving an LDKT.26  
Considering these results - along with the lower rate of receiving an LDKT and enrolling in 
a WL in for-profit dialysis centers compared to non-profit dialysis centers, - it is important 
to understand whether the education provided in non-profit dialysis centers results in better 






Study Objective 1 
The overall objective of this study was to understand if there is a difference between for-
profit dialysis centers and non-profit dialysis centers in the quality of information provided 
to the patients about transplantation options. Patients can have one of the following statuses 
during the one year after being informed:  
(a) Decide to enroll in the WL (WL enrolled) 
(b) Receive an LDKT (LDKT received) 
(c) Remain on dialysis (reference category)  
One could argue that if the association of education and odds of favorable outcomes occurring 
(after controlling for clustering effect, all available patient levels, and center level variables) 
differs between for-profit and non-profit dialysis centers, and if the type of patients being 
informed are similar across dialysis centers, it potentially indicates a  difference in the quality 
of education provided between these two types of centers. If the result of our research 
confirms the hypothesis, one could conclude that for-profit dialysis centers provide lower 
quality educational practices. 
Objective 1: To determine whether being informed about transplantation options affects 
patient’s transplantation status; and to determine whether the effect differs by ownership 
status of the dialysis center.  
Hypothesis 1: Being informed is associated with higher odds of choosing a transplantation 
option 
Hypothesis 2: Being informed by non-profit dialysis centers increases the odds of choosing 





Part 2: Aim2a- Aim2e 
History of Medicare’s ESRD program 
Medicare’s ESRD program, which was initiated in 1973, provided health insurance for ESRD 
patients regardless of their age. Medicare costs for covering ESRD during first years of new 
policy were expected to be low, as only16,000 patients required dialysis at the time.28 On 
average, Medicare reimbursed independent facilities by $138 per dialysis and hospital-based 
facilities by $156.29 Medicare’s ESRD program cost $229 million in 1973 and increased to 
$1.8 billion in 1982. Prevalent cases of ESRD also increased to 64,000.30 By 1982 Medicare’s 
ESRD program accounted for 4% of its overall expenditures.31 The increasing share of the 
ESRD program from total expenditures motivated Medicare to introduce fixed payment for 
treatments that included all costs such as labor, dialysis, dialysis machine, and tools. Starting 
in 1983, Medicare reduced reimbursements  to a per-treatment fixed rate for hospital dialysis 
centers ($131) and freestanding centers ($127). When considering inflation rate, dialysis 
centers received 35% less in 1989 than they did in 1983.12 In 1989, the Amgen 
pharmaceutical company developed the erythropoietin stimulating agent (ESA) to be used 
for ESRD patients who have severe anemia. CMS used the capitation method to pay for ESA, 
and that led to lower utilization than the FDA had recommended.12 To provide an incentive 
to use more ESAs, in 1991 Medicare implemented fee-for-service reimbursement for ESA.12 
This program (which was in effect for 20 years) provided an incentive to use more ESAs. In 
2005, separately billable reimbursement components, largely derived by ESAs, accounted for 
37% ($2.9 billion) of the dialysis care cost.32 Along with concerns about high cost of ESA, 





could result in harm. This evidence led the Food and Drug Administration to issue a statement 
on over-using the drug for patients with mild anemia.12  
Prospective Payment System 
The July 2008 congressional passage of MIPPA, which mandates reimbursement reform to 
reduce expenditures, led CMS to release their final ruling for implementing the ESRD PPS 
program in July 2010, effective from January 2011.12,13 
Under the new reimbursement system, CMS reimburses $230 per dialysis session. Payments 
for peritoneal dialysis is equal to hemodialysis to encourage more peritoneal dialysis. This 
includes dialysis cost, all injectable medications or their equivalent oral forms (ESA, iron, 
and vitamin D), and dialysis related tests.12 By 2014, oral-only drugs were also included in 
the bundled payment.33 Any administered drugs that are not specifically related to the disease 
are reimbursed separately. The new payment system eliminates the incentive to over-using 
ESA to maximize reimbursements.12 
Pay for Performance Measures 
Even though the new policy eliminates incentives to over-use ESAs, it increases the 
likelihood of inadequate treatment. CMS’s pay-for-performance rule, which included three 
measures, was designed to address this concern. The first two measures were related to 
anemia management. According to FDA recommendation, ideal hemoglobin level in dialysis 
patients is 10-12 grams per deciliter. The first measure was the percentage of Medicare 
patients in each dialysis center who had less than 10 grams per deciliter average hemoglobin 
level; the second measure was the percentage of Medicare patients in each dialysis center 





the average urea reduction ratios of more than 65%. The first measure was the most important 
measure with 50% weight; the second and third measures both had 25% weight. The national 
standard is 2% or less, 26% or less, 96% or more for first, second and third measures, 
respectively. If dialysis centers fail to meet these standards, Medicare will deduct penalties 
from their payment.28  
Research on Early Effects of New Policy 
Studies assessing early treatment trends after the new payment policy showed that the new 
policy successfully provided incentives for dialysis centers to use lower cost therapies to 
manage anemia among their patients. Studies comparing utilization of ESA in 2010 and 2011 
showed a significant decline in ESA utilization after PPS.34 Even though the decline in ESA 
was substantially due to FDA’s recommendation about more conservative usage of ESA, 
research shows that the bundled payment implementation had an impact as well.34,35 
The percentage of patients who received iron for anemia management increased by 5.5 
percentage points from 2010 to 2011.34 The percentage of patients who received intravenous 
iron increased by 10%-17% from October 2010 to October 2011.35 Utilization of other less-
expensive practices, such as using serum ferritin and blood cell transfusion, also increased 
after PPS.35–38 Increased inpatient and emergency department transfusions also increased 
after PPS, which shows a cost shift from dialysis centers to hospitals and emergency centers.39 
Overall, average hemoglobin level had been reported to be declining before 2011 and 
declined more after PPS.34,40 
Overall utilization of vitamin D has also declined, and there was a significant shift from 





a less expensive type, doxercalciferol.34,40 Use of antibiotics, levocarnitine, and alteplase has 
declined10 and use of cinacalcet and phosphate binders has increased.40  
Even though most patients could benefit from home dialysis or peritoneal dialysis, most 
patients receive in-center hemodialysis. Research shows that home dialysis and hemodialysis 
lead to the same clinical outcomes as in-center hemodialysis.41 Under PPS, for peritoneal 
dialysis Medicare reimburses dialysis centers the same amount as in-center hemodialysis. 
This payment includes payment for home dialysis training, equipment and supplies, and 
support services. Medicare also reimburses $33.44 for any training add-ons, and geography 
adjusted payments range from $20.03 to $45.84.14   
During the first year of PPS’ implementation, rate of home hemodialysis increased by the 
same rate it as it had  increasing since 2007 (0.2 percentage points per year). The use of 
peritoneal dialysis increased by about 1.2 percentage points in 2011 compared to 2010; this 
increase was not statistically significant.34,40 However, a two-year pre- and post-policy 
comparison shows a statistically significant increase in peritoneal dialysis use. Small dialysis 
organizations and non-profit dialysis centers increased peritoneal use faster than large 
organizations and for-profit dialysis centers.42 
One of the main concerns about bundling payments for dialysis - and the associated changed 
patterns in anemia management and use of other medications - was its adverse indirect effect 
on patients’ health. Wang et al, in a two-year pre-and-post policy comparison study shows 
that among elderly patients, the risk of major adverse cardiovascular events, death, 
hospitalized congestive heart failure, and venous thromboembolism were similar before and 





adverse cardiovascular events and all-cause mortality decreased significantly for African 
American patients after the PPS.43 
Public Health Significance 
Medicare expanded its coverage to ESRD patients in 1973. As the number of ESRD patients 
has increased significantly since then,  so did the Medicare’s expenditure for ESRD patients. 
Despite the increasing total number of ESRD patients covered by Medicare, it accounts for 
less than 1% of Medicare’s total population. However, this small portion of Medicare 
population accounts for a significant percentage of Medicare’s total expenditure. To address 
the issue of growing costs of the program, Medicare has changed its reimbursement policy 
multiple times since 1973, most recently in January 2011.  
The effects of this policy change on anemia management, use of vitamin D and other 
medications, and incidence and prevalence of dialysis modalities have been well studied. 
Studies have shown a shift in anemia management towards less expensive treatment and 
drugs. ESA use and doses have decreased, and the use of intravenous iron and blood 
transfusions have increased. Incidence and prevalence of home dialysis increased slightly 
after PPS.  
However, the direct and indirect effects of PPS on Medicare’s expenditure have not been 
studied well. Medicare changed its reimbursement policy for dialysis services in 2011 with 
the hope to control increasing Medicare’s ESRD program expenditure. An in-depth study on 
Medicare’s payments to dialysis centers and other providers could provide more insights on 





Study Objectives 2a-2e 
This aim explored the effect of PPS on Medicare expenditure for one-year care for patients 
who recently developed the ESRD. Total cost was further categorized to total outpatient cost, 
outpatient dialysis cost, outpatient non-dialysis cost, and inpatient cost. The effect of PPS on 
odds of having non-zero inpatient cost was further explored.  
Objective 2a: To determine effect of PPS on one-year total cost 
Objective 2b: To determine effect of PPS on one-year total outpatient cost 
Objective 2c: To determine effect of PPS on one-year outpatient dialysis cost  
Objective 2d: To determine effect of PPS on one-year outpatient non-dialysis cost  
Objective 2e: To determine effect of PPS on one-year inpatient cost  









This study used the United States Renal Data System (USRDS), a national data system that 
collects data on chronic kidney disease (CKD) and end-stage renal disease patients. The 
USRDS analyzes these data and releases an annual  report on the prevalence and incidence 
of CKD and ESRD, patient demographics, treatment modalities, and Medicare’s expenditure 
on ESRD program. USRDS is directly funded by The National Institute of Diabetes and 
Digestive and Kidney Diseases. USRDS also collaborates with CMS, the United Network for 
Organ Sharing (UNOS), and the ESRD networks. They provide a comprehensive source of 
data about ESRD patients. The following data sets from the USRDS have been used for this 
study.  
• CORE-PATIENTS: Patient Profile 
Patient profile has one record per patient in the USRDS database. This data set provides 
information on demographic such as date of birth, sex, race, ethnicity, zip code, age at first 
enrollment on WL, and ESRD-related data such as primary cause of ESRD, dialysis modality, 
date of first ESRD service, enrollment on WL, first transplant, date of death, and cause of 
death. This datafile was used to extract socio-demographic information about the patient. 
• CORE-MEDEVID: Medical Evidence Form 
Medical evidence form (CMS-2728) has information on employment status, insurance status, 
nephrology care before renal disease, primary cause of renal disease, start date of chronic 
renal dialysis, and patients’ comorbidities. This form is also the source for whether the patient 





Beginning in January 2005, this form asks whether the patient has been informed about KT 
options. If the patient has not been informed, this form provides a selection of reasons to 
choose from. This datafile was used to extract medical information such as comorbidities 
about the patient and whether the patient had been informed about the KT options.  
• CORE-WAITLIST_KI: Transplant Wait List (Kidney)  
This dataset has one record per patient per kidney WL event in the USRDS database. 
Demographic information, blood type, height and weight, previous transplants, additional 
organ enrollments, listing date and center, WL status, reason for inactive status, removal date 
from WL and reason for removal, date of death and USRDS assigned facility ID are available 
in this dataset. This datafile, along with Patient Profile, was used to exclude patients who 
enrolled on WL before filling the form CMS-2728. 
• CORE-FACILITY: Annual facility survey  
The CMS ESRD Annual Facility Survey and the CDC Dialysis Surveillance Survey is the 
sources of information on facilities. This dataset includes information on ownership status of 
the center, certification code (transplant center, dialysis center, etc.) and number of patients 
and staff personnel. The survey period is January 1 through December 31. This datafile was 
used to extract facility information. 
• CORE-PAYHIST: Payer History  
This data set contains a new record for each patient at each change in payer. It includes the 
start and end date for each period with specific payer category. If a patient’s payer category 





following groups: 1. HMO. Group Health Organization, 2. MPAB. Medicare Primary, both 
Part A and Part B, 3. MPO: Medicare Primary, Other, 4. MSP-EGHP: Medicare as Secondary 
Payer with EGHP, 5. MSP-nonEGHP: Medicare as Secondary Payer, no EGHP, 6. OTH: 
Other/Unknown, and 7. WAIT: 90 Day Waiting Period. This datafile was used to extract 
insurance coverage information about the patients. 
• Transplant dataset  
This dataset includes minimum details about all transplants from all sources. Recipient and 
donor information such as, race, ethnicity, age, gender, and blood type are available in this 
dataset. The dataset also includes the relationship of living donor and recipient, transplant 
year, total number of transplants for patient, transplant failure time, whether patient accepts 
expanded criteria donor kidneys, and USRDS-assigned facility ID. This datafile was used to 
exclude patients who received KT before filling the form CMS-2728. 
• Medicare Institutional Claims (2006-2016)/ Medicare Physician/Supplier Claims 
(2011-2016) 
There are separate claims file for each year. These files record dialysis and non-dialysis 
claims for all ESRD patients. The source of the bill, primary diagnosis code, service date, 
number of dialysis sessions (if any), and Medicare’s payment for each event is recorded. 
These datafiles were used to extract cost of services provided to ESRD patients by Medicare.  
Required variables to select target population are available in PATIENTS, MEDEVID, 
WAITLIST_KI, TX, and PAYER HISTORY sub-datasets. After identifying target 





in all datasets. Dialysis center-level information was merged to the data using the USRDS 
provider ID number which is available in MEDEVID and Institutional Claims files.  
 
Study Design 
Both Aim 1 and Aim 2 used population-based retrospective design. 
The study population for Aim 1 was defined based on the following criteria: 
(a) Patients had to be 18 to 64 years old (patients who are 65 years old and older are 
deemed medically unsuitable for transplantation). 
(b) Patients had to have the study initiation date between January 1, 2005 and  December 
31, 2016. 
(c) Patients had to have a completed CMS-2728 Form within 45 days of study initiation. 
(Medical evidence form CMS-2728 must be filled within 45 days of ESRD initiation.) 
Patients were excluded if: 
(a) They enrolled in the transplant WL or received a KT prior to the study initiation date 
and prior to completing CMS-2728 Form. 
(b) They had missing CMS-2728 form completion date. 
(c) They had a dialysis start date before study initiation date. 
(d) They were missing the provider number for their dialysis center, that links the dialysis 
center variables with each patient, or missing the ownership status or patient informed 
status. 
(e) Their date of death was erroneously recorded as being before study initiation date, 





After applying inclusion and exclusion criteria, a total of 590,601 ESRD patients were 
included in this aim. 
The study population for Aim 2 was defined based on the following criteria: 
a) Patients had to be 18 years old or older. 
b) Patients had to have their first ESRD service between January 1, 2006 and  December 
31, 2015. 
c) Patients had to have Medicare Part A and B coverage before the first ESRD service 
or during 92 days after that.  
d) Patients had to have completed a CMS-2728 Form within 45 days of study initiation. 
In this study, Medicare part A and B coverage initiation date was defined as study initiation 
date. Each patient was followed for a year after study initiation (until December 31, 2016). 
Patients were excluded if:  
a) They received a KT the day of or prior to the study end. 
b) They died the day of or prior to study end date. 
c) They had a discontinued Medicare part A and B coverage during study period. 
d) They had discontinued dialysis during the first three months after first ESRD service. 
e) They had no Medicare claims or had no dialysis sessions reported in Medicare claims. 
f) They had $0 total cos.t 
After applying inclusion and exclusion criteria, a total of 415,025 ESRD patients were 







Following tables show dependent and independent variables that were used to address study 
aims. They include the variable name, description, measures, and source of the variable. All 
the variables except education and income were available in the dataset (such as age, race, 
and ethnicity) or were derived using available variables (such as Patient’s transplantation 
status)/ Education and income are not available in the dataset. Zip code-level education and 








Table 1 Dependent Variables 
Aim Variable name Variable Description Variable type 
Aim 1 Transplantation 
status 
Patient’s transplantation status Categorical variable with three categories 
• WL enrolled 
• LDKT received 
• Remaining on dialysis (reference 
category) 
Aim 1 Patient Informed Whether patient was informed about 
Kidney transplant or not 
Categorical  
• Informed 
• Uninformed (Reference Category) 
Aim 2a Total cost The sum of all Medicare reimbursements 
for each patient over the study period 
Continuous  
Aim 2b Total Outpatient 
Cost 
The sum of Medicare reimbursements for 






Aim Variable name Variable Description Variable type 
Aim 2c Outpatient 
Dialysis Cost 
The sum of Medicare reimbursements for 
all dialysis related services provided by 
dialysis centers 
Continuous 
Aim 2d Outpatient non-
dialysis Cost 
The sum of Medicare reimbursements for 
all non-dialysis related services  
Continuous 
Aim 2e Inpatient Cost The sum of Medicare reimbursements for 
inpatient stays and skilled nursing facilities 
Continuous 
Aim 2e Non-zero Inpatient 
cost 
Whether the patient had non-zero inpatient 
cost (inpatient cost and skilled nursing 
facilities) 
Categorical variable with two categories: 









Table 2 Independent Variables 





Whether patient was informed about kidney 
transplant  
Categorical variable with two categories 




Ownership Status Ownership status of a dialysis center Categorical variable with two categories 
• Non-profit (reference category) 
• For-profit 
Aim 2a-2e Time The time elapsed since the start of the study in 
six-month period points 
Continuous variable 
Aim 2a-2e PPS Indicating whether the patient’s study 
initiation date is before or after Medicare’s 
PPS policy  
Categorical variable with two categories 
• Pre-PPS (reference category) 





Aim Variable name Variable Description Variable type 
Aim 1 
Aim 2a-2e  
Age Age at ESRD onset Continuous variable 
Aim 1 
Aim 2a-2e 
Race-Ethnicity Race/ethnicity of the patient  Categorical variable with four categories 
• Non-Hispanic white (reference 
category) 
• Non-Hispanic black 
• Hispanic 
• Other 
Aim 1  
Aim 2a-2e  
Education Percentage of adults in the patient’s zip code 




Income Median household income for the patient’s 
zip code area in dollars 
Continuous variable 





Aim Variable name Variable Description Variable type 
Aim 2a-2e • Male (reference category) 
• Female 
Aim 1 Insurance type 
 
Patient’s insurance type at time of ESRD onset  Categorical variable with five categories 
• Medicare (reference category) 
• Medicaid 
• Private insurance 
• Other insurance  
• Uninsured 
Aim 1 
Aim 2a-2e  
Employment 
Status 
Employment status of the patient  Categorical variable with five categories 
• Unemployed (reference category) 
• Employed 
• Retired due to age 










prior to ESRD 
onset 
Whether patient had nephrology care prior to 
ESRD onset  
Categorical variable with three categories 
• No (reference category) 
• Yes 
• Missing  
Aim 1 
Aim 2a-2e 
Primary cause of 
disease ESRD 
Primary cause of disease ESRD Categorical variable with five categories 
• Diabetes (reference category) 
• Hypertension 
• Glomerulonephritis 






Whether the patient had hypertension at the 
time of ESRD onset 
Categorical variable with two categories 











Whether the patient had diabetes at the time 
of ESRD onset 
Categorical variable with two categories 







Whether the patient had CVD at the time of 
ESRD onset 
Categorical variable with two categories 




Presence of cancer Whether the patient had cancer at the time of 
ESRD onset 
Categorical variable with two categories 







Whether the patient had COPD at the time of 
ESRD onset 
Categorical variable with two categories 










Aim 2a-2e  
Presence of 
disability 
Whether the patient had disability at the time 
of ESRD onset 
Categorical variable with two categories 
• No (reference category) 
• Yes 
Aim 1 
Aim 2a-2e  
BMI Body Mass Index at time of ESRD onset Continuous variable 
Aim 1 
Aim 2a-2e  
GFR EPI Glomerular Filtration Rate Epidemiology 
Collaboration time of ESRD onset 
Continuous variable 
Aim 1 
Aim 2a-2e  
GFR MDRD Glomerular Filtration Rate Modification of 
Diet in Renal Disease time of ESRD onset 
Continuous variable 
Aim 1 
Aim 2a-2e  
Current Smoker Whether the patient was a current smoker at 
the time of ESRD onset 
Categorical variable with two categories 





Aim Variable name Variable Description Variable type 
• Yes 
Aim 1 
Aim 2a-2e  
Alcohol 
dependence 
Whether the patient was dependent on alcohol 
at the time of ESRD onset 
Categorical variable with two categories 
• No (reference category) 
• Yes 
Aim 1 
Aim 2a-2e  
Drug 
dependence 
Whether the patient was dependent on drug at 
the time of ESRD onset 
Categorical variable with two categories 
• No (reference category) 
• Yes 
Aim 1 
Aim 2a-2e  
Number of 
dialysis stations 
Number of dialysis stations at the dialysis 




ESRD Network ESRD network Categorical variable with 18 categories 
• Network 1 (CT, ME, MA, NH, RI, 
VT) 





Aim Variable name Variable Description Variable type 
• Network 3 (NJ, PR, VI) 
• Network 4 (DE, PA) 
• Network 5 (DC, MD, VA, WV) 
• Network 6 (GA, NC, SC) (Reference 
Category for Aim 2a-2e) 
• Network 7 (FL) 
• Network 8 (AL, MS, TN) 
• Network 9 (IN, KY, OH) 
• Network 10 (IL) 
• Network 11 (MI, MN, ND, SD, WI) 
• Network 12 (IA, KS, MO, NE) 





Aim Variable name Variable Description Variable type 
• Network 14 (TX) (reference category 
for Aim 1) 
• Network 15 (AZ, CO, NV, NM, UT, 
WY)  
• Network 16 (AK, ID, MT, OR, WA) 
• Network 17 (AS, Guam, HI, Mariana 
Islands, Northern CA)  
• Network 18 (Southern CA) 
Aim 1 Year  Year of ESRD onset Categorical variable with 12 categories 

























The analysis for Aim 1 was conducted in two main steps. In step 1, a multi-level analysis using 
mixed effect multinomial logistic regression model was used. The outcome was defined as a 
categorical variable with three categories: (a) Deciding to enroll in the WL (WL enrolled); (b) 
Receiving an LDKT (LDKT received); and (c) Remaining on dialysis (reference category). 
To define the outcome, first the study initiation date using “Date of First ESRD Service” from 
Patient Profile dataset was defined. All patients were followed for one year after the study 
initiation date (365 days) and defined the study end date as: 
Study End Date= Study Initiation Date +365 
The following variables were used to define the outcome: “Date of first transplant,” “First 
transplant donor type,” and “First date patient is ever waitlisted” for a kidney transplant. Both date 
variables and type of donor are available in Patient Profile. Date of first transplant, date of other 
kidney transplants, and donor types are available in Transplant dataset. First date patient is ever 
waitlisted, and other possible enrollment on WL are available in Transplant Wait List (Kidney) 
as well. If a patient‘s “Date of first transplant” was recorded as a date within the study period 
(including study initiation and study end date) and “First transplant donor type” was a live donor, 
the patient was categorized as “Receiving an LDKT (LDKT received)”., Ifa patient‘s “First date 
patient is ever waitlisted” was recorded as a date within the study period (including study initiation 
and study end date) the patient was categorized as “Deciding to enroll in the WL (WL enrolled)”; 
otherwise, the patient was recorded as “Remaining on dialysis (reference category).” 
The main two independent variables of interest were Patient Informed and Ownership Status; these 





a patient about transplant options increased the odds of deciding to enroll in the WL or receiving 
an LDKT, and the second if the odds differed between for-profit and non-profit dialysis centers.  




) =  𝛾00 + 𝜇0𝑗 + 𝛾10 ∗ 𝑃𝑎𝑡𝑖𝑒𝑛𝑡 𝑖𝑛𝑓𝑜𝑟𝑚𝑒𝑑 +  𝛾11𝑂𝑤𝑛𝑒𝑟𝑠ℎ𝑖𝑝 𝑠𝑡𝑎𝑡𝑢𝑠 ∗ 𝑃𝑎𝑡𝑖𝑒𝑛𝑡_𝑖𝑛𝑓𝑜𝑟𝑚𝑒𝑑 
P= Probability that patient has the status K 
𝛾00: Grand mean of outcome across patients and centers 
𝜇0𝑗: Random intercept~𝑁(µ,  𝜎
2
µ) (to allow variability in centers)  
𝛾10: Fixed effect, representing the estimate of association between patient level variables and 
outcome 
𝛾11: Fixed effect, representing the estimate of the association between interaction of patient level 
variable and center level variable with outcome 
 
A secondary analysis was conducted for this aim to better understand the observed results from 
the above-mentioned analysis. An analysis on odds of being informed using a multi-level analysis 
using a mixed effect logistic regression model was performed. The dependent variable for this 
model was defined as Patient Informed and the main independent variable was Ownership Status 
of the dialysis center. Subgroup analysis for for-profit and non-profit dialysis centers were further 
conducted to understand the differences between the type of patients that were being informed 
between the two types of dialysis centers. SAS v. 9.4 (SAS Institute, Cary, NC) was used for all 
analysis in this aim.  
Patients’ demographic information w extracted from Patient Profile dataset. Age was calculated 
using (“Date of birth” – Study Initiation Date)/365. The number then was rounded down and used 
as Age. Gender was defined as Male (reference category) and Female using “Sex” variable in 
Patient Profile. About 0.01% of all patients in Patient Profile were missing the “Sex” variable, 





defined using “Race of patient” and “Hispanic ethnicity.” Race-Ethnicity was defined as (non-
Hispanic [NH] white, NH black, Hispanic, and other).  
The American Community Survey44,45 2011 tables linked to the USRDS data was used to define 
the level of education and income at the zip-code level for each individual. Education  was 
measured as a percentage of adults in the patient’s zip code area with high school education or 
more (continuous variable in percent); income measured as median household income for the 
patient’s zip code area (continuous variable in dollars); education  measured as a percentage of 
adults in the patient’s zip code area with some college education or more (continuous variable in 
percent). 
Other patient level variables were defined using Medical Evidence Form (CMS-2728). 
Employment status was defined using “Current employment status.” Patients were categorized as 
Unemployed (current employment status recorded as Unemployed or Homemaker), Employed 
(current employment status recorded as Employed full time or Employed part time), Retired due 
to age, Retired due to disability, and Other (current employment status recorded as any other 
category). Insurance was defined using binary variables that indicates whether the patient had 
specific insurance coverage. Each patient’s insurance was categorized as Medicare if at least one 
of the “Medicare coverage” or “Medicare Advantage” were recorded as 1, Medicaid if the 
“Medicaid coverage” was recorded as 1, Private Insurance if “Employer Group Health Insurance” 
was recorded as 1, Other if “Other medical insurance” or “DVA coverage” were recorded as 1,  or 
uninsured if “MEDCOV_NONE: No medical insurance” recorded as 1. For patients who did not 
have any insurance but were listed as “Patient is applying for ESRD Medicare Coverage,” 





Nephrology care prior to study initiation was defined using “NEPHCARE: Was patient under care 
of a nephrologist?” This was a Yes/No variable with significant proportion of missing values, so 
a category of “Missing” was included for this variable as well in the analysis.  
The primary cause of ESRD was defined using “DISGRPC: Primary Cause of Renal Failure 
detailed group.” Categories are defined as Diabetes, Hypertension, Glomerulonephritis, Polycystic 
kidney disease, and Other (for Other urologic, Other cause, Unknown cause, or Missing cause).  
The presence of comorbidities and behavioral characteristics were defined using binary (Yes/No) 
variables in Medical Evidence Form.  Body mass index (BMI), estimated Glomerular Filtration 
Rate Epidemiology Collaboration (GFR EPI), and GFR Modification of Diet in Renal Disease 
(GFR MDRD) are continuous variables available from the Medical Evidence Form.  
The analysis was controlled for the USRDS Network patient is associated with. There are 18 
USRDS networks in the US, and this variable was used as a proxy to control for geographic 
variation. The year of study initiation was also controlled for, to adjust for changes over time.  
Dialysis facility information is extracted from FACILITY: CMS/CDC ESRD Annual Facility 
dataset. The information in this data set includes the “The CMS ESRD Annual Facility Survey and 
the CDC Dialysis Surveillance Survey,” which provides information such as ownership status of 
the facility center, certification code of the facility center (dialysis center, hospital dialysis center, 
transplant center, etc.), number of staff and patients, and number of dialysis stations. Because the 
number of staff, patients, and dialysis stations were highly correlated, the number of dialysis 
stations was used as a proxy for the size of dialysis center. For each patient the provider number 
available from Medical Evidence Form (“PROVUSRD: USRDS Assigned Facility ID”) was 
assigned and linked the ownership status and number of dialysis stations from the FACILITY: 





dataset. Patient Informed Status is defined using a Yes/No variable “PATINFORMED: Patient has 
been informed of kidney transplant options” in the Medical Evidence Form.  
The number of days alive was used as a proxy for the number of days patient had during the study 
period to decide on transplantation. For the patients who remained on dialysis, this variable was 
defined as the number of days from study initiation to either date of death or the study end. Date 
of death was available in Patient Profile dataset as “Died: Date of Death.” For the patients who 
decided to enroll in the WL or to receive an LDKT this variable was defined as number of days 
from study initiation to the date of the event.  
 
Aim 2a- Aim 2e 
Interrupted time series analysis (ITSA) with ordinary least square (OLS) regressions were used to 
estimate the association between Time, PPS, and the interaction of Time and PPS with cost of care 
after controlling for other variables. An ITSA with logistic regression was used to estimate the 
association between these variables and having a non-zero inpatient cost. ITSA is a longitudinal 
study method widely used in public health and public policy research.46 The analysis for Aim 2a-
2e were conducted in six steps. First the total cost of care was calculated using Medicare claims, 
and then the cost was further categorized in four categories: Total Outpatient Cost, Outpatient 
Non-Dialysis Cost, Outpatient Dialysis Cost, and Inpatient Cost. Because 25% of patients had zero 
Inpatient Cost, the analysis of Inpatient Cost only included the patients who had non-zero Inpatient 
Cost. In another step, we explored changes in odds of having non-zero Inpatient Cost over time.  
(a) Total Cost: Calculated using Medicare reimbursement for all claims for each patient during 
the study period. Claim categories were inpatient, skilled nursing facilities, home health, 





(b) Total Outpatient Cost: Calculated using Medicare reimbursement for all institutional 
outpatient claims and all physician/supplier claims. Claim categories were home health, 
outpatient, dialysis, and physician/supplier. 
(c) Outpatient Dialysis Cost: Calculated using Medicare reimbursement for all outpatient 
dialysis services and all physician/supplier claims that had ESRD treatment facility as place 
of service. 
(d) Outpatient Non-Dialysis Cost: Calculated using Medicare reimbursements for all 
outpatient non-dialysis services and all physician/supplier claims that did not have ESRD 
treatment facility as place of service. 
(e) Inpatient Cost: Inpatient cost was calculated using Medicare reimbursement for all 
inpatient stays and skilled nursing facilities. 
To calculate outcome variables, “Date of First ESRD Service” was collected from Patient Profile 
and it was linked to Payer History data set using the USRDS assigned patient identification 
number. Payer History had a record for each change in payer. It also included information on dual 
eligibility of Medicare and Medicaid. This data was used to determine whether the patient had 
Medicare part A and B coverage at the time of first ESRD service or during 92 days after that; 
only these patients were included in the study. The reason for using 92 days is that if the patient 
does not have health insurance or has insurance other than Medicare, Medicare coverage under 
ESRD program will not initiate until the fourth month after the dialysis treatment initiation,47 The 
study initiation date was defined as the first date the Medicare part A and B initiated. Therefore, 
study initiation date could be any date from the first ESRD service and 92 days after. Each patient 
was followed up for one year after the study initiation date.  





After study initiation and end date definition, all Medicare claims were extracted for these patients 
during the study period. If a claim was recorded from a date before study initiation to a date after 
or recorded from a date before study end date to a date after end date, the following rules were 
used:  
1) If the claim was inpatient or skilled nursing facility claim, the whole cost for cost 
calculation was used. 
2) If the claim was not inpatient or skilled nursing facility claim, the cost was adjusted to the 
period that fell within the study period. 
Claims that had negative value or were missing the Medicare reimbursement were not used for 
cost calculations. Medicare reimbursements were adjusted for Consumer Price Indexes (CPIs) 
based on the year of claim through date and used in 2016 USD.48 All reimbursements were also 
adjusted for Geographic Adjustment Factor (Part A, inpatient, home health, skilled nursing 
facilities, and hospice claims) and CMS Geographic Practice Cost Index (Part B outpatient and 
physician/supplier claim) based on the year of claim through date and patient’s zip code and state 
available in Patient Profile.49–51 
For ITSA, time was defined as a continuous variable with six-month period points from January 
2006 to December 2015. For example, for patient who had their study initiation date at any point 
from January 2006 to June 2006, the time variable was defined as 0; July 2006 to December 2006 
as 1. The last time point defined was 19 for patients who had their study initiation date from July 
2015 to December 2015. The PPS variable was defined as 0 for all patients who has study initiation 
date before January 2011 (time 0-9) and defined as 1 after that (time 10-19). The interaction of the 
time and the PPS was used to estimate the effect of policy change on time trend. The formula for 





Log (Yt)= β0 + β1 Time+ β2 PPS+ β3 Timet*PPS + α1 X1 +…+ αn Xn 
Yt : The outcome variable at time t (for example total cost) 
Time: The time elapsed since the start of the study in 6-month period points 
PPS: A dummy variable indicating the pre-PPS period (coded 0) or the post-PPS period (coded 1) 
Timet*PPS: Interaction term between time and PPS 
X1- Xn: Other independent variables 
β0: The baseline level for Yt at Time=0 
β1: The change in outcome associated with one unit increase in time (representing the underlying 
pre-PPS time trend) 
β2: The immediate change following the PPS 
β3: Change in the time trend after PPS 
α1- αn: Association between other independent variables and the outcome 
 
Age, gender, race-ethnicity, education, income, employment status, nephrology care prior to 
ESRD, primary cause of ESRD, presence of comorbidities and behavioral characteristics, BMI, 
GFR EPI, GFR MDRD, and network were defined by the exact same way as the Aim 1. The 
proportion of days the patient was eligible for both Medicare and Medicaid during the study period 
was calculated using Payer History, and then was categorized as Never (the patient was not dually 
eligible during the study period), Partially dual eligible (if the patient was dual eligible for at least 
one day but not for all study period), and Always dual eligible (if patient was dual eligible for the 
entire study period). Initial Medicare eligibility was defined as a categorical variable with four 
categories of ESRD, Age, Disability, and Other using “First Medicare enrollment reason code” 





Provider was derived from claims and was defined as the facility/provider that the patient received 
the most of their dialysis sessions. The provider to facility survey was then linked using the same 
method described for Aim 1 to extract Ownership Status and the number of dialysis stations. 
Human Subject Considerations  
The study used USRDS data which is a de-identified data and does not have patient information. 
The study was reviewed with Health Science Center Institute review board prior to access the data. 
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Informing End-Stage Renal Disease patients about kidney transplantation options increases the 
likelihood of kidney transplant waiting list (WL) enrollment and live donor kidney transplant 
(LDKT) receipt. Patients in for-profit dialysis centers have a lower rate of WL enrollment and 
LDKT receipt. This study examined if the ownership status of dialysis centers modified the 
association between informing patients about transplantation options and patients’ transplantation 
status. Multi-level analysis using mixed-effect multinomial logistic regression was performed 
using the United States Renal Data System (USRDS) data (January 2005-December 2017). The 
study showed that informing patients improved the odds of WL enrollment and LDKT receipt. 
However, the effect of informing patients on transplantation status was less pronounced at for-
profit as compared with non-profit centers (Non-profit: WL-enrollment OR: 2.23 [95%CI: 2.07-
2.40], LDKT-receipt OR: 3.35 [95%CI: 2.65-4.25]; For-profit: WL-enrollment OR: 1.73 [95%CI: 
1.66-1.79], LDKT-receipt OR: 2.35 [95%CI: 2.08-2.66]), although, the odds of informing patients 
was higher for for-profit centers, and type of patients informed were similar across both types of 
centers.  Information provided by for-profit centers was less effective and potentially lower quality 
than those provided by non-profit centers.  Standardized guidelines for transplantation information 






More than 120,000 patients develop End-Stage Renal Disease (ESRD) in the United States (US) 
each year1, and require renal replacement therapies, which include dialysis and/or kidney 
transplantation (hereafter referred to as transplantation).  The two transplantation options available 
to ESRD patients are: 1) enrolling in the deceased donor waiting list (WL); or 2) receiving a Living 
Donor Kidney Transplant (LDKT). For many ESRD patients, transplantation, as opposed to 
dialysis, remains the medically optimal renal replacement therapy because transplantation 
improves survival and is cost-effective.1–3 In 2017, the adjusted all-cause mortality rate was 
165/1,000 for dialysis patients and 29/1,000 for transplantation patients. In the same year, total 
Medicare ESRD expenditures/person/year were about $90,600 for dialysis patients and $35,800 
for transplantation patients.1 However, in 2016 only 14% of ESRD patients enrolled in the WL or 
received a deceased or live donor kidney transplant within one year of ESRD onset.1 
 
Prior studies showed that informing ESRD patients about transplantation options increased the 
likelihood of choosing transplantation options.4–6  Nevertheless, there is no standardized 
transplantation information provision guideline for dialysis centers to follow. This has resulted in 
a wide variation in transplantation information provided, in terms of both the quality (defined as 
details and intensity), and quantity (defined as number and duration) of the information sessions. 
In a study involving 170 dialysis centers, there was high level of variation between centers in both 
the quality and quantity of transplantation information sessions provided to ESRD patients.7 The 
quality ranged from oral recommendations for transplantation evaluation, referral to external 
transplantation information programs, to detailed intensive discussions about transplantation.7 The 





patients, had higher proportions of patients enrolling in WL.7 A national survey-based study 
concluded that most nephrologists (81%) believed that the ideal duration for educating patients 
about transplantation is >20 minutes; however, 57% nephrologists spent <20 minutes.8 This study 
also showed that duration of information sessions provided to patients was positively correlated 
with the quality of the sessions.8  
 
Furthermore, studies show that there were differences in transplantation information provided 
between for-profit and non-profit dialysis centers. For-profit dialysis centers were less likely than 
non-profit dialysis centers to use longer duration and more intensive transplantation information 
sessions.7–9  Differences in informational quality may influence transplantation decisions made by 
patients being served by for-profit versus non-profit dialysis centers. Studies showed a lower rate 
of choosing transplantation options among patients in for-profit dialysis centers than among those 
in non-profit dialysis centers.5,10–12 Although there are differences in transplantation information 
provided between for-profit and non-profit dialysis centers, it remains unknown if provision of 
differential quality of information between these dialysis centers explains the lower rate of 
choosing transplantation options among ESRD patients in for-profit dialysis centers, or if these 
differences are due to number and type of ESRD patients being informed.  
 
In this study, we examined if the ownership status (for-profit vs. non-profit) modified the 
association between informing patient about transplantation options and patient’s transplantation 
status by using the interaction term between ownership status of a dialysis center and whether the 
patient was informed about transplantation options (informed vs.  not informed). If the association 





differs between for-profit and non-profit dialysis centers, it might indicate a difference in quality 
of information provided between these dialysis centers, and consequently might explain the 
observed variation in patient’s transplantation status. In addition, this study also examined the 
likelihood of patients being informed about transplantation options in for-profit and non-profit 
dialysis centers, to examine if there is a difference in quantity of information sessions provided by 
these centers, and also examined the type of patients being informed by these centers.  
 
Methods 
Study design and Data Source 
This study used the United States Renal Data System (USRDS) data from January 2005-December 
20171. USRDS is a national database that includes information on all patients with ESRD, and all 
dialysis facilities in the United States. We used the following datasets: Patient Profile, Medical 
Evidence Form (CMS-2728), Transplant WL (Kidney), Transplant, and ESRD Annual Facility 
Survey. The CMS-2728 Form is typically completed by the dialysis facility for each patient within 
45 days of ESRD service initiation. We also used the U.S. 2010 Census data linked to the USRDS 
to obtain the level of education and income at the zip-code-level for each patient.13,14 The study 
begins on January 2005 because prior to this month the CMS-2728 Form did not have data on 
whether the patient was informed about transplantation options.   
 
Since ESRD diagnosis date is not present in the USRDS data, the USRDS researcher’s guide 
utilizes the date of first ESRD service provision as the date of ESRD incidence.15 In this study, the 
date of first ESRD service provision was considered the study initiation date for each patient and 





information for each patient was extracted from the ESRD Annual Facility Survey conducted 
during the year of study initiation. To be eligible for this study, patients (a) had to be 18-64 years 
old at study initiation (patients >65 years are deemed medically unsuitable for transplantation); (b) 
had to have the study initiation date between 1st January 2005 and 31st December 2016; and (c) 
had to have a completed CMS-2728 Form within 45 days of study initiation. Patients were 
excluded if they (a) enrolled in the transplant WL or received a kidney transplant prior to the study 
initiation date or prior to completing CMS-2728 Form; (b) had missing medical evidence form 
(CMS-2728) date; (c) had a dialysis start date before study initiation date; (d) had missing provider 
number for their dialysis center (required for data linkage), or missing ownership status or patient 
informed status; or (e) date of death was erroneously recorded as being before study initiation, 
waiting list enrollment, or transplantation dates. A total of 588,550 ESRD patients were included 
in this study. 
Dependent variable 
The dependent variable, “Transplantation Status”, was defined as the first transplantation-related 
decision that a patient made during the study period. However, if the patient enrolled in WL and 
received LDKT after that within a year, the patient was classified as having received LDKT. This 
variable was categorized into three categories: (a) WL enrolled; (b) LDKT received; and (c) 








The two independent variables of interest were “Ownership Status” and “Patient Informed Status”. 
Ownership Status was a binary variable measuring for-profit ownership status of a patient’s 
dialysis center (for-profit coded as 1, and non-profit coded as 0). Patient Informed Status was a 
binary variable measuring whether a patient was informed about transplantation options within 45 
days of study initiation (informed patients coded as 1, not informed coded as 0). The data on 
whether or not patient was informed was obtained from the CMS-2728 form, and this study only 
included patients who had completed CMS-2728 form within 45 days of study initiation. The 
interaction between Ownership Status and Patient Informed Status was used to determine whether 
the ownership status of a dialysis center modified the association between informing patients and 
transplantation status.  
 
Other covariates controlled for were, patient sociodemographic, clinical, and behavioral 
characteristics at study initiation date, and dialysis center characteristics. Patient socio-
demographic characteristics included age at study initiation (continuous variable in years); gender 
(male, female); race-ethnicity (non-Hispanic [NH] white, NH black, Hispanic, other); education  
measured as a percent of adults in the patient’s ZIP code area with some college education or more 
(continuous variable in percent); income measured as median household income for the patient’s 
ZIP code area (continuous variable in USD); employment status at study initiation (unemployed, 
employed, retired due to age, retired due to disability, other); and insurance status at study initiation 
(Medicare, Medicaid, private insurance, other insurance, uninsured). Past studies show that 
education and income at the U.S. zip-code-level are valid measures for patient’s socio-economic 





initiation (yes, no, missing); primary cause of ESRD (diabetes, hypertension, glomerulonephritis, 
polycystic kidney disease, and other); binary variables indicating the presence of comorbidities 
such as hypertension, diabetes, cardiovascular disease [CVD], cancer and chronic obstructive 
pulmonary disease [COPD] at study initiation; presence of disability at study initiation (yes, no); 
Body Mass Index (BMI) at study initiation (continuous variable); Glomerular Filtration Rate 
Epidemiology Collaboration [GFR-EPI] at study initiation (continuous variable); and GFR 
Modification of Diet in Renal Disease [GFR-MDRD] at study initiation (continuous variable). 
Patient behavioral characteristics included being a smoker at study initiation (yes, no); alcohol 
dependence at study initiation (yes, no); and drug dependence at study initiation (yes, no).  
 
Dialysis center characteristics included: the number of dialysis stations in a dialysis center (proxy 
for size of the dialysis center – continuous variable); and the regional ESRD network the dialysis 
center belonged to (18 network categories). In addition to patient and dialysis center 
characteristics, year of study initiation (2005-2016) and number of days alive after study initiation 
(continuous variable in days) were also controlled for. If a patient died during the study period, it 
was calculated as the number of days from the beginning of the study period to death; if not, it was 
recorded as 365 days. 
Analysis 
All analyses were performed using SAS v.9.4 (SAS Institute, Cary, NC). Table 1 illustrates 
descriptive statistics for all independent variables by transplantation status categories. Table 2 
descriptively illustrates characteristics associated with patients who were informed versus not 
informed about transplantation options, and further explores if these associations were different 





Characteristics associated with transplantation status   
Multi-level analysis using mixed-effect multinomial logistic regression estimation was performed 
to evaluate the modifying effect of ownership status on the association between patient informed 
status and transplantation status, after controlling for other covariates (Table 3). Since the study 
data are organized at two levels (center and patient level), we accounted for correlations between 
individual patients who are nested within a dialysis center by using random intercepts for centers 
in the mixed-effect regression estimation. Income was logarithmically transformed to improve 
model-fit and statistical significance in the regressions.  
Characteristics associated with whether or not patients were informed about transplantation 
options 
In order to estimate if a dialysis center’s ownership status affected the likelihood of patients being 
informed, as well as to understand if the modifying effect of the ownership status was due to 
differences in types of patients being informed in the dialysis centers with different ownership 
status, we performed three multi-level analysis using mixed-effect logistic regressions (Table 4). 
First the effect of ownership status on the likelihood of a patient being informed was estimated 
after controlling for other covariates, and then sub-group analyses were performed to see if 
characteristics of patients being informed differed by the two type of ownership status (not-profit 
and for-profit). Income was logarithmically transformed to improve model-fit and statistical 
significance in the regressions. 
Sensitivity analysis 
About 88,000 patients died during the study period, or were reported to be medically unfit for 
transplantation. These patients had a shorter time or lower chance of choosing a transplantation 





patients were informed by transplant centers. These patients have a higher chance of being 
informed and receiving transplantation due to the service mission and goal of these centers (and 
not necessarily because of the effect of patient information). Sensitivity analysis was performed 
by excluding both the patients who died/were declared medically unfit during the study period, 
and those informed by transplant centers. A total of 491,590 ESRD patients were included in the 
sensitivity analysis.  
Study Results 
Characteristics associated with transplantation status 
Of 588,550 patients, 12.26% (72,127) enrolled in WL, 1.40% (8,223) received an LDKT, and 
86.35% (508,200) remained on dialysis, (Table 1). Patients who chose either of the transplantation 
options were less likely to be treated in for-profit dialysis centers (78 to 81%), as compared with 
patients continuing on dialysis (84%). In addition, patients who chose either of the transplantation 
options were more likely to be informed about the transplantation options (93 to 95%), as 
compared with patients continuing on dialysis (84%). 
Patients who were younger, were male, were NH-White, belonged to more educated and higher 
income ZIP code areas, were employed, and had private insurance were more likely to choose 
either of the transplantation options. Clinically, patients who had nephrology care prior to study 
initiation, did not have certain chronic ailments such as diabetes, CVD, cancer and COPD, were 
not disabled, had lower average BMI, and had slightly worse glomerular filtration rates at study 
initiation were more likely to choose either of the transplantation options. Patients who were 
smokers, and alcohol or drug dependent were less likely to choose either of the transplantation 
options. Regionally, patients belonging to the northeastern centers were more likely to choose 





to choose either of the transplantation options. Patients alive for more days after study initiation 
were more likely to choose either of the transplantation options.  
Characteristics associated with whether or not patients were informed about transplantation 
options 
Of 588,550 patients, 84.78% (498,967) were informed and 15.22% (89,583) were not informed 
about transplantation options (Table 2). Majority of the patients initiated dialysis at a for-profit 
dialysis center (83.69%) and these patients were more likely to be informed about transplant 
options compared with patients who initiated dialysis at a non-profit dialysis center (85.63% vs 
80.41%). Informed patients were more likely to enroll in transplant WL (13.38% vs. 6.01%) and 
to receive an LDKT (1.57% vs. 0.42%) compared with patients who were not informed. Although 
for-profit dialysis centers had a higher proportion of informed patients than non-profit dialysis 
centers, a lower proportion of informed patients at for-profit dialysis centers versus non-profit 
chose either of the transplantation options (14.22% vs. 18.92%). 
Overall, patients who were younger, were male, and were not non-Hispanic white, belonged to 
higher income ZIP code areas, and were employed and privately insured were more likely to be 
informed. Education, although significant, did not have a meaningful group difference. Clinically, 
patients who had nephrology care prior to study initiation, had no comorbidities such as CVD, 
cancer and COPD, but had hypertension, were not disabled, and had worse GRF values were more 
likely to be informed. The difference in BMI, between patients who were informed and not 
informed, was statistically significant but not clinically meaningful. Behaviorally, smokers, and 
drug or alcohol dependent patients were less likely to be informed. The likelihood of being 





Characteristics associated with being informed (versus not) were examined separately for patients 
at for-profit and non-profit dialysis centers (Table 2). The socio-demographic, clinical and 
behavioral patient characteristics associated with being informed were similar irrespective of the 
ownership status, and were in the same direction as described above for the overall sample.  
Multiple regression examining characteristics associated with transplantation status   
Given individual patients were nested within dialysis centers, intra-class correlation coefficients 
(ICCs) were calculated for each outcome category, i.e., WL-enrolled and LDKT-received. We 
found that 11% (ICC=0.11, WL-enrolled) and 21% (ICC=0.21, LDKT-received) of variations 
were explained by clustering. In addition to random intercept, regressions with random coefficients 
were also performed, especially to assess the interaction effects across the different levels. 
However, we were not able to get complete parameter estimates due to the lack of convergence. 
Based on these findings a random intercept model was used for the final regression (Table 3).  
The regression analysis (Table 3) established that ownership status modified the effect of patient 
informed status on transplantation status. Overall informing patients statistically increased the 
odds of patients enrolling in WL and receiving LDKT, as compared with not informing patients. 
Nevertheless, the adjusted odds were significantly lower for patients at for-profit dialysis centers 
versus patients at non-profit dialysis centers (Non-profit dialysis centers: (1) WL-enrolled OR: 
2.23 [95%CI: 2.07-2.40]; (2) LDKT-received OR: 3.35 [95%CI: 2.65-4.25]. For-profit dialysis 
centers: (1) WL-enrolled OR: 1.73 [95%CI: 1.66-1.79]; (2) LDKT-received OR: 2.35 [95%CI: 
2.08-2.66]). The patient socio-demographic, clinical, behavioral, dialysis center, and other 
characteristics were similarly associated with choosing either of the two transplantation options in 






Sensitivity analysis performed after excluding patients who died/were deemed medically unfit for 
transplantation during the first year after study initiation (study period), or patients who were 
informed by transplant centers provided the same results. (Appendix: Table 1) 
Multiple regression examining characteristics associated with whether or not patients were 
informed about transplantation options 
Three sets of multi-level analyses using mixed-effect logistic regression estimations were 
performed to examine characteristics associated with whether or not patients were informed about 
transplantation options. In the first logistic regression analysis all patients were included. This 
analysis showed that patients at for-profit dialysis centers were more likely to be informed about 
transplantation options than patients at non-profit dialysis centers (Table 4) (OR: 1.32 [95%CI: 
1.21-1.44]).  The second and third logistic regressions were performed to examine characteristics 
associated with being informed among patients treated at for-profit and non-profit dialysis centers, 
respectively. These regressions showed that the characteristics of patients associated with being 
informed were the same between for-profit and non-profit dialysis centers, and the direction of the 
association were same as those estimated in the first logistic regression containing the entire patient 
sample (Table 4), and also similar to the unadjusted descriptive analyses performed above (Table 
2). However, as compared with the descriptive statistics (Table 2) the association of race-ethnicity 
with being informed reversed in the three adjusted regressions, such that non-Hispanic whites were 
more likely to be informed in the adjusted regressions.  
Discussion 
This is the first study to use the nationally representative USRDS data to examine the modifying 
effect of a dialysis center’s ownership status on the association between informing a patient about 





for-profit dialysis centers were less likely to choose either of the transplantation options as 
compared with informed patients at non-profit dialysis centers. Furthermore, the odds of patients 
being informed at the for-profit dialysis centers were higher than non-profit dialysis centers. In 
addition, the type of patients being informed (in terms of the socio-demographic, clinical and 
behavioral characteristics), in centers with either types of ownership status were similar, and not 
statistically different. 
Past studies were consistent with our results and showed that for-profit dialysis centers, compared 
with non-profit dialysis centers, had lower overall adjusted likelihood of patients enrolling in WL 
or receiving an LDKT.5,10–12  Moreover, patients who were informed about transplantation options 
were more likely to choose a transplantation option.4–6 However this is the first study, to our 
knowledge, that has looked at whether patients from for-profit dialysis centers had a lower 
likelihood of choosing either of the transplantation options in spite of being informed as compared 
with patients from non-profit dialysis centers, thereby possibly indicating a quality difference in 
information provided based on ownership status. 
This study established that for-profit dialysis centers informed more patients and informed similar 
type of patients as compared with non-profit dialysis centers, yet the information provided by for-
profit dialysis centers was less effective in improving the likelihood of choosing transplantation 
options. These findings suggest that although for-profit dialysis centers are investing effort in 
informing more patients about transplantation options, the quality and intensity of information 
provided is probably lacking. Previous studies support the possibility of differential quality of 
transplantation information by ownership status, by showing that providers at for-profit dialysis 
centers were less likely to engage in high quality more intense informational strategies that 





The study findings highlight the challenges associated with lack of guidelines for a standardized 
transplantation information program. More than 80% of ESRD patients receive care in for-profit 
dialysis centers. The disparity in the effectiveness of transplantation information, overall low rates 
of patients seeking transplantation options, and the excessive cost burden of ESRD and dialysis on 
federal funds and the society, raises significant concerns about the absence of standardized 
transplantation information programs. Past studies have evaluated well-designed and intensive 
informational strategies such as clinical and home-based education, culturally sensitive education, 
information provided to both patients and family members, one-on-one discussions, and 
sufficiently long and detailed information programs. The studies show that these strategies have 
the potential to increase the willingness to receive transplantation, WL enrollment, and LDKT  
receipt.4–6,18–22 In 2014, a report on best practices for transplant education for live kidney donations 
was published, based on a consensus conference attended by transplant professionals, patients, and 
other stakeholders.23 The importance of providing transplant-related information to reduce 
transplant barriers was discussed and summarized in this conference report.23 Nevertheless, more 
work needs to be done to develop comprehensive guidelines for information for both types of 
kidney transplantation given the clinical and economic burden at stake.  
Our study also had other interesting findings about characteristics associated with patients who 
chose either of the transplantation options. These findings were similar to previous findings. Socio-
demographically, past studies also found that patients who were younger,5,6,11,24–26 were 
male,5,6,11,24 were NH-White,24,25,27 had higher education level,25 belonged to a higher 
socioeconomic status,5,27 and were employed6,25 were more likely to choose either of the 
transplantation options. Clinically, past studies found that patients who had nephrology care before 





BMI5,11 were more likely to choose either of the transplantation option. Behaviorally, past studies 
found that smokers and alcohol or drug dependent patients were less likely to choose a 
transplantation option.5,11 Regional trends with higher likelihood of choosing a transplantation 
option among the northeastern centers and lower among southern centers were also similar in the 
literature.10,28 
Few studies investigated factors associated with informing a patient about transplantation 
options.4,6,29–31 However, the findings of these studies were similar to our study. These studies also 
found that patients who were younger,4 male,4,29,30 and employed6 were more likely to be informed. 
Patients who had nephrology care before ESRD onset,4,6 did not have comorbid conditions such 
as CVD, cancer, COPD,4  had better functional status,31 and were not drug or alcohol dependent,4,6 
were more likely to be informed. There was no consensus on the association between race-
ethnicity4,6,29,30 and being informed in the literature.  
Insurance has been shown to be an important factor associated with access to transplantation. Past 
studies showed that patients who have private insurance are more likely to be informed about 
transplantation options,4,6 to be evaluated for a transplant,32 and to choose a transplantation option 
by enrolling in WL or receiving an LDKT.5,6,11,25 Transplant patients need to receive 
immunosuppressive medications to prevent transplant rejections. These medications are highly 
costly and transplant patients rely on their health insurance coverage for these medications. Private 
insurance provides better and longer coverage of immunosuppressive medications. Currently 
Medicare provides coverage for kidney transplantation and covers 80% of immunosuppressive 
medications for 36 months after the transplantation.33 Discontinued coverage might result in 
nonadherence to immunosuppressants and eventually transplant failure, and past studies showed 





receive these medications might be a barrier to both patient’s decision to pursue a transplant option 
and nephrologist’s decision to inform the patient about these options. Our findings suggest that 
higher rates of choosing transplantation options and being informed about transplantation, among 
privately insured patients, is potentially correlated with their coverage of immunosuppressive 
medications. Therefore, extension of Medicare coverage for these medications beyond 36 months 
has the potential to overcome this barrier and improve receipt of kidney transplants.  
Our study has some limitations. First, there is no information in the data about the duration and 
type of transplantation information sessions provided to the ESRD patients. Hence, this study only 
controlled for a binary variable indicating whether or not a patient was informed about 
transplantation options. Second, the data did not have information on patient-level education and 
income, which might be associated with using dialysis centers of different ownership status, 
likelihood of patients being informed about transplantation options, and having access to 
transplantation. These associations can confound the adjusted effects estimated in this study. 
However, this study used the U.S. 2010 Census data to control for zip-code-level income and 
education variables, which have been shown to be consistent measures for personal socio-
economic status.16,17 Irrespective of the limitations, it is important to understand that the USRDS 
is a population-based nationally representative data with high quality clinical, socio-demographic, 
and dialysis center level information. Consequently, the findings of this study are critical for 
understanding the relationship between patient informed status and transplantation status, and the 
modifying effect of a dialysis center’s ownership status.  
In conclusion, this study found a differential effect of informing patients on transplantation status 
based on the ownership status of the dialysis centers. Information provided by for-profit dialysis 





dialysis centers informing more patients and informing similar type of patient as compared with 
non-profit dialysis centers. This study’s findings highlight the importance of informing patients 
about various transplantation options, and the need for developing guidelines to standardize 
transplantation information provided, to ensure similar informational quality across centers.   
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Table 1 Descriptive Statistics Illustrating the Patient, Dialysis Center, and Other Characteristics Associated with Transplantation Status 
 All ESRD patients 
N= 588,550 
   










Ownership Status (%)     
        For-profit 80.64 78.03 84.21 <0.0001 
        Non-profit 19.36 21.97 15.79  
Patient Informed Status (%)        
Informed  92.54 95.44 83.51 <0.0001 
Not informed  7.46 4.56 16.49  
Patient Socio-Demographic Characteristics  
Age at study initiation (years) 47.30 (11.71)┼ 42.76 (13.01) ┼ 51.99 (9.97) ┼ <0.0001 
Gender (%)     
Male 63.33 64.84 57.70 <0.0001 
Female  36.67 35.16 42.30  
Race-ethnicity (%)        
Non-Hispanic White 42.06 66.60 41.28 <0.0001 
Non-Hispanic Black 28.97 11.99 35.70  
Hispanic 20.64 16.39 17.59  
Other 8.33 5.02 5.43  
Education (percent some college education & above in ZIP code area) 48.61 (14.56) ┼ 51.26 (14.87) ┼ 46.02 (14.71) ┼ <0.0001 
Income (median household income in ZIP code area – USD) 52,841 (20,843) ┼ 59,298 (22,718) ┼ 46,893 (18,255) ┼ <0.0001 
Employment status at study initiation (%)     
Unemployed 30.91 20.58 39.75 <0.0001 
Employed 33.36 50.80 13.93  
Retired due to age 5.45 4.12 7.15  
Retired due to disability 20.40 10.37 33.83  
Other 9.88 14.13 5.34  
Insurance status at study initiation (%)        
Medicare 28.73 16.55 44.24 <0.0001 
Medicaid 17.16 8.79 23.89  
Private insurance 43.68 62.59 21.81  
Other insurance  10.00 11.71 9.29  
Uninsured 0.43 0.36 0.77  
Patient Clinical Characteristics 
Nephrology care prior to study initiation (%)     
Yes 66.66 68.71 52.65 <0.0001 
No 24.35 24.43 33.71  
Missing 8.99 6.86 13.64  
Primary cause of ESRD (%)        
Diabetes 43.03 25.16 51.33 <0.0001 
Hypertension 22.82 17.62 24.51  
Glomerulonephritis 18.54 34.88 8.37  
Polycystic kidney disease 4.85 7.31 1.67  
Other 10.76 15.03 14.12  
Presence of hypertension at study initiation (%)        





 All ESRD patients 
N= 588,550 
   










No 12.66 16.77 14.32  
Presence of diabetes at study initiation (%)        
Yes 48.40 28.75 59.76 <0.0001 
No 51.60 71.25 40.24  
Presence of CVD* at study initiation (%)        
Yes 25.89 17.21 45.25 <0.0001 
No 74.11 82.79 54.75  
Presence of cancer at study initiation (%)        
Yes 1.68 1.97 4.61 <0.0001 
No 98.32 98.03 95.39  
Presence of COPD at study initiation (%)        
Yes 1.86 1.03 7.26 <0.0001 
No 98.14 98.97 92.74  
Presence of Disability at study initiation (%)        
Yes 4.52 2.02 16.71 <0.0001 
No 95.48 97.98 83.29  
BMI at study initiation (continuous) 29.16 (6.71) ┼ 27.78 (6.20) ┼ 30.96 (8.96) ┼ <0.0001 
GFR EPI at study initiation (continuous) 8.39 (4.99) ┼ 8.18 (4.92) ┼ 9.62 (6.27) ┼ <0.0001 
GFR MDRD at study initiation (continuous) 8.66 (4.06) ┼ 8.13 (3.86) ┼ 9.8 (4.71) ┼ <0.0001 
Patient Behavioral Characteristics 
Smoker at study initiation (%)     
Yes 4.57 3.78 9.91 <0.0001 
No 95.43 96.22 90.09  
Alcohol dependence at study initiation (%)        
Yes 1.21 0.29 2.76 <0.0001 
No 98.79 99.71 97.24  
Drug dependence at study initiation (%)        
Yes 0.52 0.28 2.85 <0.0001 
No 99.48 99.72 97.15  
Dialysis Center Characteristics 
Number of dialysis stations (count) 21.12 (9.79) ┼ 20.33 (9.76) ┼ 21.64 (9.76) ┼ <0.0001 
Regional ESRD Network (%)     
Network 1 (CT, ME, MA, NH, RI, VT) 4.09 5.85 2.53 <0.0001 
Network 2 (NY) 7.23 8.73 5.23  
Network 3 (NJ, PR, VI) 4.11 4.80 4.16  
Network 4 (DE, PA) 5.22 4.48 3.76  
Network 5 (DC, MD, VA, WV) 6.05 6.58 5.79  
Network 6 (GA, NC, SC) 7.15 4.33 10.44  
Network 7 (FL) 3.85 4.12 6.40  
Network 8 (AL, MS, TN) 5.54 3.94 6.42  
Network 9 (IN, KY, OH) 5.53 8.40 7.62  
Network 10 (IL) 4.54 6.54 3.99  
Network 11 (MI, MN, ND, SD, WI) 6.61 9.30 5.52  
Network 12 (IA, KS, MO, NE) 3.35 4.40 3.59  





 All ESRD patients 
N= 588,550 
   










Network 14 (TX) 10.34 8.61 10.09  
Network 15 (AZ, CO, NV, NM, UT, WY)  4.91 6.57 4.75  
Network 16 (AK, ID, MT, OR, WA) 2.42 3.56 2.84  
Network 17 (AS, Guam, HI, Mariana Islands, Northern CA)  8.88 3.41 4.03  
Network 18 (Southern CA) 7.08 3.98 7.86  
Other Variables 
Year of study initiation (%)     
2005 5.16 8.40 4.95 <0.0001 
2006 9.17 12.16 8.11  
2007 8.80 10.31 8.18  
2008 8.75 9.80 8.35  
2009 9.17 9.84 8.61  
2010 8.83 8.18 8.59  
2011 8.98 7.62 8.49  
2012 9.15 7.33 8.49  
2013 8.88 6.91 8.64  
2014 8.23 6.51 8.95  
2015 7.61 6.58 9.34  
2016 7.27 6.36 9.30  
Number of days alive after study initiation (days) 362.35 (23.57) ┼ 364.47 (10.00) ┼ 336.02 (81.03) ┼ <0.0001 
 
Note: *CVD: atherosclerotic heart disease, congestive heart failure, peripheral vascular disease, cerebrovascular disease, and other cardiac problem 
          ┼ Mean with standard deviation in parenthesis presented for continuous variables 
          Abbreviations: ESRD - End-Stage Renal Disease; WL -Wait List; LDKT - Live Donor Kidney Transplant; CVD - Cardiovascular Disease; COPD - Chronic Obstructive Pulmonary Disease; BMI 







Table 2 Descriptive Statistics Illustrating the Patient, Dialysis Center, and Other Characteristics Associated with Patients Being Informed 
About Transplantation Options 
 All ESRD patients 
N=588,550 
ESRD patients at For-profit dialysis centers 
N=492,555 
83.69% 
ESRD patients at Non-profit dialysis centers 
N= 95,995 
16.31% 



















Transplantation Status (%)          
WL enrolled 13.38 6.01 <.0001 12.77 6.07 <.0001 16.68 5.79 <.0001 
LDKT received 1.57 0.42  1.45 0.42  2.24 0.41  
Continuing on dialysis 85.05 93.57  85.78 93.51  81.08 93.80  
Ownership Status (%)          
For-profit 84.53 79.01 <.0001 100 100 <.0001 0.00 0.00 <.0001 
Non-profit 15.47 20.99  0.00 0.00  100 100  
Patient Socio-Demographic Characteristics 
Age at study initiation (years) 51.05 (10.5) ┼ 52.59 (9.79) ┼ <.0001 51.14 (10.43) ┼ 52.62 (9.77) ┼ <.0001 50.57 (10.89) ┼ 52.49 (9.89) ┼ <.0001 
Gender (%)          
Male 58.69 57.42 <.0001 58.55 57.16 <.0001 59.42 58.40 0.01 
Female  41.31 42.58  41.45 42.84  40.58 41.60  
Race-ethnicity (%)              
Non-Hispanic White 41.14 44.98 <.0001 40.71 44.33 <.0001 43.50 47.42 <.0001 
Non-Hispanic Black 34.72 33.60   34.89 33.82   33.76 32.76  
Hispanic 18.31 15.91   18.96 17.01   14.79 11.77  
Non-Hispanic other 5.83 5.51   5.44 4.84   7.96 8.04  
Education (percent some college education 
& above in ZIP code area) 46.44 (14.68) ┼ 46.22 (14.97) ┼ 
<.0001 
46.12 (14.57) ┼ 45.60 (14.81) ┼ 
<.0001 
48.18 (15.14) ┼ 48.59 (15.36) ┼ 
0.01 
Income (median household income in ZIP 
code area – USD) 47,951 (18,937) ┼ 46,925 (18,073) ┼ 
<.0001 
47,696 (18,723) ┼ 46,389 (17,612) ┼ 
<.0001 
49,348 (20,007) ┼ 48,943 (19,582) ┼ 
0.15 
Employment status at study initiation (%)          
Unemployed 37.99 40.65 <.0001 38.15 40.67 <.0001 37.16 40.54 <.0001 
Employed 17.93 10.70  17.72 10.77  19.04 10.40  
Retired due to age 6.81 7.41  6.91 7.41  6.27 7.42  
Retired due to disability 31.04 36.37  31.08 36.33  30.84 36.49  
Other 6.23 4.87  6.14 4.80  6.69 5.15  
Insurance status at study initiation (%)                
Medicare 41.30 45.55 <.0001 41.57 45.73 <.0001 39.87 44.88 <.0001 
Medicaid 22.47 25.01   22.40 24.90   22.80 25.42  
Private insurance 26.09 19.31   26.33 19.97   24.81 16.83  
Other 9.44 9.26   9.04 8.65   11.62 11.55  
Uninsured 0.70 0.87   0.66 0.75   0.90 1.32  
Patient Clinical Characteristics 
Nephrology care prior to study initiation 
(%)* 
         
Yes 56.39 44.58 <.0001 55.52 43.73 <.0001 61.11 47.80 <.0001 
No 31.16 39.54  31.17 38.26  31.12 44.34  
Missing 12.45 15.88  13.31 18.01  7.77 7.86  
Primary cause of ESRD (%)                
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Hypertension 24.59 22.07  25.40 23.32  20.20 17.37  
Glomerulonephritis 10.36 7.91  9.86 7.49  13.05 9.50  
Polycystic kidney disease 2.32 1.15  2.25 1.15  2.70 1.15  
Other 12.52 20.45  11.97 18.53  15.54 27.64  
Presence of hypertension at study initiation 
(%)                
Yes 86.45 82.50 <.0001 86.40 82.81 <.0001 86.73 81.34 <.0001 
No 13.55 17.50  13.60 17.19  13.27 18.66  
Presence of diabetes at study initiation (%)                
Yes 57.89 58.16 0.13 58.28 59.01 0.0003 55.78 54.98 0.04 
No 42.11 41.84  41.72 40.99  44.22 45.02  
Presence of CVD* at study initiation (%)                
Yes 41.39 48.63 <.0001 41.00 47.94 <.0001 43.50 51.25 <.0001 
No 58.61 51.37  59.00 52.06  56.50 48.75  
Presence of cancer at study initiation (%)                
Yes 3.76 6.71 <.0001 3.66 6.16 <.0001 4.31 8.81 <.0001 
No 96.24 93.29  96.34 93.84  95.69 91.19  
Presence of COPD at study initiation (%)                
Yes 6.09 8.82 <.0001 5.97 8.42 <.0001 6.77 10.30 <.0001 
No 93.91 91.18  94.03 91.58  93.23 89.70  
Presence of Disability at study initiation 
(%)                
Yes 13.49 23.47 <.0001 13.51 22.93 <.0001 13.37 25.47 <.0001 
No 86.51 76.53   86.49 77.07   86.63 74.53  
BMI at study initiation (continuous) 30.69 (8.61) ┼ 30.73 (9.26) ┼ <.0001 30.76 (8.63) ┼ 30.83 (9.25) ┼ <.0001 30.30 (8.49) ┼ 30.36 (9.27) ┼ 0.0004 
GFR EPI at study initiation (continuous) 9.33 (5.97) ┼ 10.10 (6.91) ┼ <.0001 9.37 (5.99) ┼ 10.16 (6.94) ┼ <.0001 9.15 (5.84) ┼ 9.89 (6.79) ┼ <.0001 
GFR MDRD at study initiation (continuous) 9.55 (4.58) ┼ 10.10 (4.94) ┼ <.0001 9.59 (4.59) ┼ 10.14 (4.95) ┼ <.0001 9.37 (4.49) ┼ 9.93 (4.89) ┼ <.0001 
Patient Behavioral Characteristics 
Smoker at study initiation (%)          
Yes 8.94 10.47 <.0001 8.67 9.74 <.0001 10.37 13.25 <.0001 
No 91.06 89.53  91.33 90.26  89.63 86.75  
Alcohol dependence at study initiation (%)                
Yes 2.29 3.90 <.0001 2.21 3.71 <.0001 2,73 4.59 <.0001 
No 97.71 96.10  97.79 96.29  97.27 95.41  
Drug dependence at study initiation (%)                
Yes 2.30 3.75 <.0001 2.18 3.14 <.0001 2.98 6.07 <.0001 
No 97.70 96.25  97.82 96.86  97.02 93.93  
Dialysis Center Characteristics 
Number of dialysis stations (count) 21.58 (9.74) ┼ 21.4 (9.96) ┼ <.0001 21.51 (9.25) ┼ 21.46 (9.32) ┼ <.0001 21.99 (12.04) ┼ 21.18 (12.07) ┼ <.0001 
Regional ESRD Network (%)          
Network 1 (CT, ME, MA, NH, 






Network 2 (NY) 5.60 5.13   3.88 3.12   14.97 12.69  
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Network 4 (DE, PA) 3.89 4.32   3.86 4.13   4.06 5.03  
Network 5 (DC, MD, VA, WV) 5.75 6.28   5.77 6.60   5.64 5.11  
Network 6 (GA, NC, SC) 9.70 11.33   9.87 11.99   8.73 8.88  
Network 7 (FL) 6.17 5.42   6.75 6.17   3.00 2.57  
Network 8 (AL, MS, TN) 6.23 6.50   6.46 7.19   5.00 3.91  
Network 9 (IN, KY, OH) 7.30 7.83   7.64 8.24   5.44 6.31  
Network 10 (IL) 4.16 3.72   4.46 4.36   2.51 1.29  
Network 11 (MI, MN, ND, SD, 
WI) 5.73 5.57   4.79 4.59   10.85 9.25 
 
Network 12 (IA, KS, MO, NE) 3.53 3.79   3.26 3.38   5.02 5.36  
Network 13 (AR, LA, OK) 4.77 4.37   5.28 4.81   1.97 2.75  
Network 14 (TX) 10.57 7.53   12.04 8.95   2.51 2.11  
Network 15 (AZ, CO, NV, NM, 
UT, WY)  4.74 5.05   4.70 5.64   4.97 2.85 
 
Network 16 (AK, ID, MT, OR, 
WA) 2.52 4.33   2.15 2.71   4.56 10.42 
 
Network 17 (AS, Guam, HI, 
Mariana Islands, Northern CA)  4.66 4.40   4.22 3.57   7.08 7.51 
 
Network 18 (Southern CA) 7.71 7.70   8.40 9.27   3.93 1.81  
Other Variables 
Year of study initiation (%)          
2005 4.69 6.91 <.0001 4.39 6.73 <.0001 6.31 7.58 <.0001 
2006 7.65 11.88   7.18 11.69   10.19 12.63  
2007 7.66 11.77   7.30 11.78   9.59 11.79  
2008 7.89 11.38   7.64 11.45   9.24 11.14  
2009 8.41 10.23   8.25 10.22   9.31 10.29  
2010 8.42 9.66   8.35 9.91   8.81 8.70  
2011 8.48 8.86   8.51 9.07   8.29 8.07  
2012 8.86 6.85   8.99 6.73   8.12 7.28  
2013 9.12 5.99   9.41 5.79   7.55 6.71  
2014 9.35 5.90   9.72 6.07   7.36 5.27  
2015 9.76 5.41   10.15 5.35   7.63 5.62  
2016 9.71 5.16   10.10 5.22   7.61 4.91  
      
Note: *CVD: atherosclerotic heart disease, congestive heart failure, peripheral vascular disease, cerebrovascular disease, and other cardiac problem  
                ┼ Mean with standard deviation in parenthesis presented for continuous variables 
          Abbreviations: ESRD - End-Stage Renal Disease; WL -Wait List; LDKT - Live Donor Kidney Transplant; CVD - Cardiovascular Disease; COPD - Chronic Obstructive Pulmonary Disease; BMI 








Table 3 Adjusted Odds Ratios Demonstrating the Effect of Patient, Dialysis Center, and Other Characteristics on Transplantation Status 
 WL enrolled  
OR Estimate (95% CI) 
(Reference: Continuing on dialysis) 
LDKT received 
OR Estimate (95% CI) 
(Reference: Continuing on dialysis) 
Informed versus Not informed Comparison:   
For For-profit 1.73 (1.66, 1.79)** 2.35 (2.08, 2.66)** 
For Non-Profit 2.23 (2.07, 2.40)** 3.35 (2.65, 4.25)** 
Patient Socio-Demographic Characteristics     
Age at study initiation 0.97 (0.97, 0.97)** 0.94 (0.94, 0.94)** 
Gender (Reference: Male)   
Female 0.82 (0.81, 0.84)** 0.78 (0.74, 0.82)** 
Race-ethnicity (Reference: Non-Hispanic White)   
Non-Hispanic Black 0.77 (0.75, 0.79)** 0.22 (0.20, 0.24)** 
Hispanic 1.05 (1.02, 1.08)** 0.67 (0.62, 0.72)** 
Non-Hispanic Other 1.09 (1.05, 1.13)** 0.39 (0.35, 0.44)** 
Education  1.01 (1.01, 1.01)* 1.01 (1.01, 1.01)** 
Logarithm of Income 1.50 (1.46, 1.55)** 2.10 (1.94, 2.27)** 
Employment status at study initiation (Reference: Unemployed)   
 
Employed 1.64 (1.60, 1.68)** 2.47 (2.31, 2.65)** 
Retired due to age 1.28 (1.23, 1.34)** 1.69 (1.49, 1.93)** 
Retired due to disability 1.07 (1.04, 1.09)** 1.06 (0.97, 1.16) 
Other 1.34 (1.30, 1.39)** 1.80 (1.65, 1.96)** 
Insurance status at study initiation (Reference: Medicare)   
Medicaid 0.89 (0.87, 0.91)** 0.74 (0.67, 0.82)** 
Private insurance 1.78 (1.74, 1.82)** 2.90 (2.70, 3.12)** 
Other 1.27 (1.23, 1.31)** 2.06 (1.88, 2.25)** 
Uninsured 0.45 (0.39, 0.50)** 0.41 (0.28, 0.60)** 
 
Patient Clinical Characteristics   
Nephrology care prior to study initiation (Reference: No)   
Yes 1.76 (1.73, 1.80)** 2.02 (1.91, 2.14)** 
Missing  1.11 (1.07, 1.15)** 1.13 (1.02, 1.25)* 
Primary cause of ESRD (Reference: Diabetes)   
Hypertension 1.00 (0.97, 1.03) 1.14 (1.03, 1.25)** 
Glomerulonephritis 1.34 (1.30, 1.38)** 2.19 (2.00, 2.40)** 
Polycystic kidney disease 1.77 (1.68, 1.86)** 2.13 (1.89, 2.41)** 
Other 0.80 (0.77, 0.83)** 1.04 (0.94, 1.15) 
Presence of hypertension at study initiation (Reference: No)   
Yes 1.16 (1.12, 1.19)** 1.12 (1.05, 1.20)** 
Presence of diabetes at study initiation (Reference: No)   
Yes 0.96 (0.93, 0.98)** 0.74 (0.68, 0.80)** 
Presence of CVD at study initiation (Reference: No)   
Yes 0.66 (0.65, 0.68)** 0.60 (0.56, 0.64)** 
Presence of Cancer at study initiation (Reference: No)   
Yes 0.43 (0.41, 0.46)** 0.42 (0.35, 0.49)** 
Presence of COPD at study initiation (Reference: No)   
Yes 0.54 (0.51, 0.58)** 0.46 (0.38, 0.57)** 
Presence of Disability at study initiation (Reference: No)   
Yes 0.47 (0.45, 0.49)** 0.38 (0.32, 0.44)** 





 WL enrolled  
OR Estimate (95% CI) 
(Reference: Continuing on dialysis) 
LDKT received 
OR Estimate (95% CI) 
(Reference: Continuing on dialysis) 
GFR EPI at study initiation 0.98 (0.98, 0.99)** 0.98 (0.98, 0.99)** 
GFR MDRD at study initiation 0.99 (0.99, 0.99)** 0.98 (0.97, 0.99)** 
Patient Behavioral Characteristics   
Smoker at study initiation (Reference: No)   
Yes 0.51 (0.49, 0.53)** 0.42 (0.37, 0.47)** 
Alcohol dependence at study initiation (Reference: No)   
Yes 0.94 (0.87, 1.01) 0.29 (0.20, 0.42)** 
Drug dependence at study initiation (Reference: No)   
Yes 0.26 (0.24, 0.29)** 0.25 (0.17, 0.37)** 
Dialysis Center Characteristics   
Number of dialysis stations 0.99 (0.99, 0.99)** 0.99 (0.99, 0.99)** 
Regional ESRD Network (Reference: Network 14 - TX)     
         Network 1 (CT, ME, MA, NH, RI, VT) 1.39 (1.27, 1.53)** 1.65 (1.39, 1.96)** 
         Network 2 (NY) 1.27 (1.17, 1.38)** 1.65 (1.41, 1.92)** 
         Network 3 (NJ, PR, VI) 1.06 (0.97, 1.16) 1.26 (1.06, 1.49)** 
         Network 4 (DE, PA) 1.51 (1.39, 1.64)** 1.39 (1.17, 1.64)** 
         Network 5 (DC, MD, VA, WV) 0.96 (0.88, 1.03) 1.15 (0.98, 1.34) 
         Network 6 (GA, NC, SC) 0.73 (0.68, 0.78)** 0.57 (0.48, 0.66)** 
         Network 7 (FL) 0.59 (0.54, 0.63)** 0.63 (0.54, 0.75)** 
         Network 8 (AL, MS, TN) 1.02 (0.95, 1.10) 1.04 (0.88, 1.23) 
         Network 9 (IN, KY, OH) 0.83 (0.77, 0.89)** 1.21 (1.05, 1.39)** 
         Network 10 (IL) 1.16 (1.06, 1.26)** 1.77 (1.51, 2.07)** 
         Network 11 (MI, MN, ND, SD, WI) 1.34 (1.24, 1.45)** 1.85 (1.60, 2.14)** 
         Network 12 (IA, KS, MO, NE) 0.92 (0.84, 1.01) 1.03 (0.87, 1.23) 
         Network 13 (AR, LA, OK) 0.72 (0.66, 0.79)** 0.68 (0.56, 0.83)** 
         Network 15 (AZ, CO, NV, NM, UT, WY)  0.88 (0.82, 0.96)** 1.03 (0.88, 1.20) 
         Network 16 (AK, ID, MT, OR, WA) 0.68 (0.61, 0.75)** 0.75 (0.62, 0.91)** 
         Network 17 (AS, Guam, HI, Mariana I, N. CA)  1.75 (1.62, 1.90)** 0.84 (0.70, 1.01) 
         Network 18 (Southern CA) 0.79 (0.74, 0.86)** 0.42 (0.36, 0.50)** 
Other Variables   
Year of study initiation (Reference: 2005)   
         2006 1.13 (1.07, 1.18)** 0.95 (0.85, 1.05) 
         2007 1.10 (1.05, 1.16)** 0.83 (0.74, 0.92)** 
         2008 1.09 (1.04, 1.14)** 0.81 (0.72, 0.90)** 
         2009 1.12 (1.07, 1.18)** 0.82 (0.73, 0.91)** 
         2010 1.11 (1.06, 1.17)** 0.71 (0.63, 0.80)** 
         2011 1.13 (1.08, 1.19)** 0.66 (0.59, 0.74)** 
         2012 1.14 (1.08, 1.19)** 0.65 (0.57, 0.73)** 
         2013 1.06 (1.01, 1.11)* 0.58 (0.52, 0.66)** 
         2014 0.89 (0.85, 0.94)** 0.49 (0.44, 0.56)** 
         2015 0.77 (0.73, 0.80)** 0.46 (0.41, 0.52)** 
         2016 0.71 (0.68, 0.75)** 0.42 (0.37, 0.48)** 
Number of days alive after study initiation 1.01 (1.01, 1.01)** 1.01 (1.01, 1.02)** 
Note: * : Significant at P<0.05, ** : Significant at P<0.01 
 Abbreviations: ESRD - End-Stage Renal Disease; WL -Wait List; LDKT - Live Donor Kidney Transplant; CVD - Cardiovascular Disease; COPD - Chronic Obstructive Pulmonary Disease; BMI - 





Table 4. Adjusted Odds Ratios Demonstrating the Effect of Patient, Dialysis Center, and Other Characteristics on Patients Being 
Informed About Transplantation Options 
 All dialysis centers For-profit dialysis centers Non-profit dialysis centers 
 OR Estimate (95% CI) OR Estimate (95% CI) OR Estimate (95% CI) 
Ownership status (Reference:  Non-profit)    
For-profit 1.32 (1.21, 1.44)**   
Patient Socio-Demographic Characteristics    
Age at study initiation 0.98 (0.98, 0.98)** 0.98 (0.98, 0.98)** 0.98 (0.98, 0.98)** 
Gender (Reference: Male)    
Female 0.97 (0.95, 0.99)** 0.97 (0.95, 0.99)** 0.96 (0.92, 0.99)* 
Race-ethnicity (Reference: Non-Hispanic-White)    
Non-Hispanic-Black 0.95 (0.93, 0.98)** 0.96 (0.93, 0.99)** 0.93 (0.88, 0.98)** 
Hispanic 0.97 (0.94, 0.99)* 0.97 (0.94, 1.01) 0.96 (0.89, 1.03) 
Non-Hispanic-other 0.94 (0.90, 0.98)* 0.94 (0.90, 0.99)* 0.96 (0.88, 1.05) 
Education  0.99 (0.99, 0.99)** 0.99 (0.99, 0.99)** 0.99 (0.99, 0.99)** 
Logarithm of Income 1.18 (1.14, 1.22)** 1.20 (1.15, 1.24)** 1.15 (1.07, 1.23)** 
Employment status at study initiation (Reference: Unemployed)    
Employed 
 
1.47 (1.42, 1.51)** 1.43 (1.38, 1.48)** 1.65 (1.53, 1.77)** 
Retired due to age 1.11 (1.07, 1.15)** 1.12 (1.07, 1.16)** 1.06 (0.98, 1.15) 
Retired due to disability 1.04 (1.02, 1.06)** 1.04 (1.01, 1.06)** 1.10 (1.05, 1.16)** 
Other 1.23 (1.18, 1.28)** 1.23 (1.18, 1.28)** 1.23 (1.12, 1.35)** 
Insurance status at study initiation (Reference: Medicare)    
Medicaid 0.96 (0.94, 0.99)** 0.97 (0.94, 0.99)* 0.94 (0.89, 0.99)* 
Private insurance 1.24 (1.20, 1.27)** 1.24 (1.21, 1.27)** 1.28 (1.20, 1.36)** 
Other 1.10 (1.06, 1.14)** 1.08 (1.04, 1.12)** 1.15 (1.08, 1.23)** 
Uninsured 0.61 (0.55, 0.67)** 0.63 (0.56, 0.70)** 0.53 (0.44, 0.64)** 
Patient Clinical Characteristics 
 
   
Nephrology care prior to study initiation (Reference: No)    
Yes 1.69 (1.66, 1.72)** 1.64 (1.60, 1.67)** 1.92 (1.84, 2.01)** 
Missing 0.93 (0.91, 0.96)** 0.90 (0.87, 0.93)** 1.09 (1.01, 1.19)* 
Primary cause of ESRD (Reference: Diabetes)    
Hypertension 0.93 (0.91, 0.96)** 0.94 (0.91, 0.97)** 0.91 (0.85, 0.97)** 
Glomerulonephritis 0.99 (0.96, 1.03) 1.00 (0.96, 1.05) 0.94 (0.87, 1.02) 
Polycystic kidney disease 1.51 (1.40, 1.63)** 1.49 (1.37, 1.62)** 1.56 (1.32, 1.83)** 
Other 0.62 (0.60, 0.64)** 0.65 (0.63, 0.67)** 0.55 (0.51, 0.58)** 
Presence of hypertension at study initiation (Reference: No)    
Yes 1.12 (1.10, 1.15)** 1.11 (1.08, 1.14)** 1.17 (1.11, 1.24)** 
Presence of diabetes at study initiation (Reference: No)    
Yes 1.00 (0.97, 1.02) 1.00 (0.97, 1.03) 0.98 (0.93, 1.04) 
Presence of CVD at study initiation (Reference: No)    
Yes 0.86 (0.85, 0.88)** 0.87 (0.85, 0.89)** 0.83 (0.80, 0.87)** 
Presence of Cancer at study initiation (Reference: No)    
Yes 0.57 (0.55, 0.59)** 0.60 (0.57, 0.63)** 0.49 (0.45, 0.53)** 
Presence of COPD at study initiation (Reference: No)    
Yes 0.86 (0.84, 0.89)** 0.87 (0.84, 0.91)** 0.82 (0.77, 0.88)** 
Presence of Disability at study initiation (Reference: No)    






       Note: * : Significant at P<0.05, ** : Significant at P<0.01 
          Abbreviations: ESRD - End-Stage Renal Disease; WL -Wait List; LDKT - Live Donor Kidney Transplant; CVD - Cardiovascular Disease; COPD - Chronic Obstructive Pulmonary Disease; BMI 
- Body Mass Index; GFR EPI - Glomerular Filtration Rate Epidemiology Collaboration; GFR MDRD - Glomerular Filtration Rate Modification of Diet in Renal Disease.  
BMI at study initiation 0.99 (0.99, 0.99)** 0.99 (0.99, 0.99)** 0.99 (0.99, 0.99)** 
GFR EPI at study initiation 0.99 (0.99, 0.99)** 0.99 (0.99, 0.99)** 0.99 (0.99, 0.99)** 
GFR MDRD at study initiation 0.99 (0.99, 0.99)** 0.99 (0.99, 0.99)** 0.99 (0.98, 0.99)** 
Patient Behavioral Characteristics    
Smoker at study initiation (Reference: No)    
Yes 0.97 (0.95, 1.00) 0.99 (0.96, 1.03) 0.93 (0.87, 0.99)* 
Alcohol dependence at study initiation (Reference: No)    
Yes 0.77 (0.73, 0.80)** 0.74 (0.70, 0.78)** 0.82 (0.74, 0.91)** 
Drug dependence at study initiation (Reference: No)    
Yes 0.76 (0.72, 0.79)** 0.81 (0.77, 0.78)** 0.65 (0.59, 0.72)** 
Dialysis Center Characteristics    
Number of dialysis stations 1.01 (1.01, 1.01)** 1.01 (1.01, 1.01)** 0.99 (0.99, 0.99)** 
Regional ESRD Network (Reference: Network 14 - TX)    
         Network 1 (CT, ME, MA, NH, RI, VT) 0.57 (0.47, 0.70)** 0.56 (0.45, 0.71)** 0.70 (0.42, 1.16) 
         Network 2 (NY) 0.76 (0.64, 0.90)** 0.76 (0.62, 0.93)** 0.99 (0.64, 1.53) 
         Network 3 (NJ, PR, VI) 1.03 (0.85, 1.26) 1.21 (0.96, 1.51) 0.99 (0.62, 1.59) 
         Network 4 (DE, PA) 0.75 (0.63, 0.89)** 0.79 (0.65, 0.95)* 0.94 (0.59, 1.51) 
         Network 5 (DC, MD, VA, WV) 0.79 (0.67, 0.92)** 0.78 (0.66, 0.93)** 1.12 (0.70, 1.78) 
         Network 6 (GA, NC, SC) 0.76 (0.66, 0.88)** 0.73 (0.63, 0.85)** 1.24 (0.80, 1.94) 
         Network 7 (FL) 0.85 (0.72, 0.99)* 0.84 (0.71, 0.98)* 1.19 (0.72, 1.95) 
         Network 8 (AL, MS, TN) 0.82 (0.70, 0.96)* 0.77 (0.65, 0.90)** 1.47 (0.92, 2.37) 
         Network 9 (IN, KY, OH) 0.85 (0.74, 0.99)* 0.88 (0.75, 1.03) 1.01 (0.64, 1.58) 
         Network 10 (IL) 0.85 (0.71, 1.01) 0.84 (0.70, 1.01) 1.63 (0.94, 2.81) 
         Network 11 (MI, MN, ND, SD, WI) 0.77 (0.65, 0.90)** 0.78 (0.65, 0.93)** 1.02 (0.66, 1.56) 
         Network 12 (IA, KS, MO, NE) 0.73 (0.62, 0.87)** 0.74 (0.61, 0.90)** 0.99 (0.62, 1.56) 
         Network 13 (AR, LA, OK) 0.86 (0.74, 1.01) 0.88 (0.74, 1.04) 0.79 (0.46, 1.33) 
         Network 15 (AZ, CO, NV, NM, UT, WY)  0.69 (0.60, 0.80)** 0.68 (0.58, 0.80)** 1.11 (0.72, 1.71) 
         Network 16 (AK, ID, MT, OR, WA) 0.60 (0.50, 0.73)** 0.71 (0.57, 0.88)** 0.64 (0.41, 0.98)* 
         Network 17 (AS, Guam, HI, Mariana I, N. CA)  0.74 (0.63, 0.89)** 0.79 (0.65, 0.96)* 0.98 (0.64, 1.52) 
         Network 18 (Southern CA) 0.67 (0.57, 0.79)** 0.67 (0.57, 0.79)** 1.25 (0.76, 2.07) 
Other Variables    
Year of study initiation (Reference: 2005)    
        2006 0.95 (0.91, 0.99)* 0.95 (0.90, 0.99)* 0.94 (0.86, 1.03) 
        2007 0.98 (0.94, 1.02) 0.98 (0.93, 1.03) 0.98 (0.89, 1.07) 
        2008 1.07 (1.03, 1.12)** 1.09 (1.04, 1.14)** 1.04 (0.95, 1.15) 
        2009 1.34 (1.28, 1.40)** 1.38 (1.31, 1.44)** 1.22 (1.11, 1.34)** 
        2010 1.48 (1.42, 1.55)** 1.51 (1.44, 1.59)** 1.40 (1.27, 1.54)** 
        2011 1.62 (1.55, 1.69)** 1.67 (1.59, 1.75)** 1.48 (1.34, 1.64)** 
        2012 2.40 (2.29, 2.52)** 2.68 (2.54, 2.82)** 1.62 (1.46, 1.79)** 
        2013 2.85 (2.71, 2.99)** 3.30 (3.12, 3.48)** 1.64 (1.48, 1.82)** 
        2014 2.96 (2.82, 3.10)** 3.27 (3.10, 3.45)** 1.97 (1.77, 2.20)** 
        2015 3.52 (3.35, 3.69)** 3.96 (3.75, 4.19)** 2.11 (1.89, 2.36)** 
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Abstract 
Background: In July 2008, congress passed Medicare Improvements for Patients and Providers 
Act (MIPPA) that mandated reimbursement reform to reduce Medicare end stage renal disease 
(ESRD) program expenditure, which led CMS to release final ruling for implementation of the 
ESRD Prospective Payment System (PPS)  or bundled payment on July 2010, effective from 
January 2011. In this study we examined the effect of PPS on Medicare’s cost of one year care for 
newly developed ESRD patients. Total cost was further categorized into total outpatient cost, 
outpatient dialysis cost, outpatient non-dialysis cost, and inpatient cost. we also examined the 
changes in odds of having a non-zero inpatient cost.  
Methods: We used the United States Renal Data System (USRDS) data collected from January 
2006 to December 2016. Interrupted time series analysis (ITSA) with ordinary least square (OLS) 
regressions were used to estimate the association between Time, PPS, and the interaction of Time 
and PPS with cost of care after controlling for patient and dialysis center characteristics. An ITSA 
with logistic regression was also used to estimate the association between these variables and odds 
of having a non-zero inpatient cost. 
Results: Before PPS, Medicare’s total expenditure was steady over time, however right after PPS, 
the expenditure decreased by time: -0.84% [95% CI: (-0.97, -0.72)]. Total outpatient cost and 
Outpatient dialysis cost both had a downward trend before PPS: -0.55% [95% CI: (-0.61, -0.48)] 





immediately increased after PPS, the decreasing trend continued over time. Outpatient non-dialysis 
cost was growing by time before PPS, 1.31% [95% CI: (1.12, 1.50)], and the growth continued 
with an immediate decrease after PPS. Inpatient cost was increasing with time before PPS, 1.84% 
[95% CI: (1.67, 2.00)]; inpatient cost significantly dropped after PPS and continued to decline over 
time. Odds of having a non-zero inpatient cost was declining before PPS and with immediate drop 
in the probability after PPS, the probability continued to decline over time.  
Discussion: PPS policies have potential to reduce the cost of care and policy change in one setting 








Since 1973 Medicare has provided health insurance for end stage renal disease (ESRD)patients 
regardless of their age. Medicare cost for covering ESRD during first years of new policy was 
expected to be low, as only 16,000 patients required dialysis in 1973.1 Over years, number of 
ESRD patients and cost of healthcare provided for these patients have grown. By 1982 total 
number of ESRD patients increased to 64,000 and total expenditure for these patients increased to 
$1.8 billion.2 By 1982 Medicare’s ESRD program accounted for 4% of its overall expenditure.3 
Increasing share of ESRD program from total expenditures, motivated Medicare to introduce fixed 
payment for treatments that included all costs such as labor, dialysis, dialysis machine, and tools 
in 1983.1,4 Considering inflation rate, in 1989 dialysis centers received 35% less than what they 
used to receive in 1983.1 In 1989 the erythropoietin stimulating agent (ESA), developed by 
pharmaceutical company Amgen, was approved for use in dialysis patients suffering from severe 
anemia. CMS used capitated method to pay for ESA,5 which resulted in lower use of ESA than 
what was recommended by FDA.1 To provide an incentive to use more ESAs, in 1991 Medicare 
implemented fee-for-service reimbursement for ESA.1 This program (which was in effect for 20 
years) provided incentive to use more ESAs over years. In 2005, separately billable reimbursement 
components, largely derived by ESAs, accounted for 37% (2.9 billion) of the dialysis care cost.6  
Cost of Medicare’s ESRD program continued to grow over years, to the point that while 
Medicare’s ESRD population accounted for 1% of its total population, in 2016 it has accounted 
for about 7.2% ($35,4 billion) of Medicare fee-for-service spending.7 The most recent change in 
reimbursement policy was implemented in Jan-2011. In July 2008, congress passed the “Medicare 
Improvements for Patients and Providers Act (MIPPA)”. MIPPA mandates reimbursement reform 





Prospective Payment System  (PPS) or bundled payment in July 2010, effective from January 
2011.1,8  
Under the new reimbursement system, CMS initially reimbursed $230 per dialysis session (the 
reimbursement is subject to change by year). The reimbursement covered dialysis cost, all 
injectable medications or their equivalent oral forms (ESA, iron, and vitamin D), and dialysis 
related tests.1,8 Any administered drugs that are not specifically related to the disease would be 
reimbursed separately. The new payment system, eliminated the incentive to over-using ESA to 
maximize reimbursements.1 
One of the main concerns about any bundle payment system is the incentive to underuse 
medications or to replace them with less expensive medications in order to reduce the cost of care 
and maximize the profitability. For example, it was a concern that changes in anemia management 
practice in dialysis centers would adversely affect patient’s health. Preliminary analysis showed 
that ESA dosing has reduced after 2011. Even though the decline in ESA has been substantially 
related to FDA’s recommendation about more conservative usage of ESA specially for patients 
with mild anemia,9,10 which was published in June 2011, research showed that bundle payment 
implementation had an impact as well.11 Utilization of less expensive anemia management 
practices  such as intravenous iron, serum ferritin and blood cell transfusion utilization both in 
inpatient and outpatient setting increased as well.10,12–15 Compared with 2009, increased utilization 
of less expensive vitamin D also was observed after 2011.9,16 Under the bundled payment, 
Medicare incentivizes peritoneal dialysis (PD) by offering the equal payment as hemodialysis 
despite lower medication costs, on average, in PD; according to early research after 2011 use of 
PD increased about 1.2 percentage points in 2011 compared to 2010, however this increase was 





statistically significant increase in PD use; small dialysis organizations and non-profit dialysis 
centers increased PD use faster than large organizations and for-profit dialysis centers.17 Wang et 
al, in a 2-year pre-and-post policy comparison study showed that among elderly patients, risk of 
major adverse cardiovascular events, death, hospitalized congestive heart failure, and venous 
thromboembolism were similar before and after policy; the risk of stroke was lower for study 
period of after policy. Risk of major adverse cardiovascular events and all-cause mortality 
decreased significantly for African American patients after the policy change.18 Despite well 
studied effects of PPS on utilization and health outcome, direct and indirect effects of PPD on cost 
of care has not been well studied. Our goal was to explore the effect of PPS on Medicare 
expenditure for one-year of care for patients who recently developed the ESRD. Cost categories 
of interest were total cost, total outpatient cost, outpatient dialysis cost, outpatient non-dialysis 
cost, and inpatient cost. 
 
Methods 
Study design and Data Source 
This study used USRDS data from January 2006 to December 2016. USRDS is a national data 
system that includes information on all patients with ESRD, Medicare claims for ESRD patients 
covered by Medicare, and information about dialysis facilities in the United States. We extracted 
data from the following USRDS datasets: Patient Profile, Medical Evidence Form (CMS-2728), 
Institutional claims, Physician/Supplier claims, and CMS/CDC ESRD Annual Facility Survey. We 
also used the American Community Survey (ACS) 2011, 5 year estimate public use data linked to 






To be eligible for this study, patients  (a) had to be 18 years old and above;  (b) had to have their 
first ESRD service between 1st January 2006 and 31st December 2015; (c) had to have Medicare 
Part A and B coverage before the first ESRD service or during 92 days after that; (d) had to have 
a completed CMS-2728 Form within 45 days of study initiation. 
In this study, the first day patient had Medicare part A and B coverage during the 92 days of first  
ESRD services was defined as study initiation date. Each patient was followed for a year after 
study initiation (until December 31st, 2016). Patients were excluded if they (a) received a kidney 
transplant the day of or prior to the study end; (b) died the day of or prior to study end date; (c) 
had discontinued Medicare part A and B coverage during study period; (d) had discontinued 
dialysis during the first 3 months after first ESRD service; (e) had no Medicare claims or had no 
dialysis sessions reported in Medicare claims; (f) had 0$ total cost. A total of 415,025 ESRD 
patients were included in this study. 
Dependent variables 
The dependent variables were defined as 5 categories of direct medical cost reimbursed by 
Medicare during the study period, and a binary variable indicating whether Medicare 
reimbursement for inpatient services for a patient during the study period was 0 or non-zero. We 
defined the cost categories as: 
(a) Total cost: The sum of all Medicare reimbursements for each patient over the study period 
(b) Total outpatient cost: The sum of Medicare reimbursements for outpatient and physician/ 
supplier services 
(c) Outpatient dialysis cost: The sum of Medicare reimbursements for all dialysis related 





involving dialysis services and all physician/supplier claims that had ESRD treatment 
facility as place of service.  
(d) Outpatient non-dialysis cost: The sum of Medicare reimbursements for all outpatient non-
dialysis services. This cost equals total outpatient cost minus outpatient dialysis cost. 
(e) Inpatient cost: The sum of Medicare reimbursements for inpatient stays and skilled nursing 
facilities. 
(f) Non-zero inpatient cost: A binary variable indicating whether Medicare’s reimbursement 
for inpatient care for the patient was 0 or non-zero.   
All costs were reported in 2016 USD using the Consumer Price Index’s (CPI’s)21 medical care 
component. Costs were adjusted for geographic variation using CMS Geographic Adjustment 
Factor for Part A and CMS Geographic Practice Cost Index for Part B claims.22–24 
 
Independent variables 
The two independent variables of interest were Time and PPS. Time was defined as a continuous 
variable measuring time from January 2006 to ESRD onset date for each patient. Time is measured 
in 6-month period points. Time was defined as 0 for all patients with study initiation date from 
January 2006 to June 2006, and 19 for all patients with study initiation from July 2015 to December 
2015. PPS was a binary variable measuring whether the patient developed ESRD on or after 
January 2011, time10 to 19, (coded as 1)  with patient developing ESRD before January 2011 as 
the reference category, time 0 to 9, (coded as 0). The interaction of Time and PPS was used to 
determine whether PPS modified the association between Time and cost of care.  
Other independent variables were patient characteristics at the time of ESRD onset and dialysis 





demographic, clinical, and behavioral. Socio-demographic characteristics included age at ESRD 
onset (continuous variable in years); gender (male, female); race-ethnicity (non-Hispanic [NH] 
white, NH black, Hispanic, and other); education measured as a percentage of adults in the 
patient’s ZIP code area with some college education or more (continuous variable in percent); 
income measured as median household income for the patient’s ZIP code area (continuous variable 
in dollars); employment status (unemployed, employed, retired due to age, retired due to disability, 
and other); Medicare and Medicaid Dual Eligibility during the study period (never dual eligible, 
partially dual eligible, and always dual eligible); initial Medicare eligibility reason (ESRD, age, 
disability, other). Past studies show that education and median household income at the U.S. zip 
code level are valid proxies for patient’s individual education and income.25,26 Patient clinical 
characteristics included receipt of  nephrology care prior to ESRD onset (yes, no, missing); 
primary cause of ESRD (diabetes, hypertension, glomerulonephritis, polycystic kidney disease, 
and other); binary variables indicating the presence or absence of comorbidities such as 
hypertension, diabetes, cardiovascular disease [CVD], cancer and chronic obstructive pulmonary 
disease [COPD]; presence of disability (yes, no); BMI (continuous variable); Hemoglobin 
(continuous variable); Glomerular Filtration Rate Epidemiology Collaboration [GFR EPI] 
(continuous variable); and GFR Modification of Diet in Renal Disease [GFR MDRD] (continuous 
variable). Patient behavioral characteristics included being a current smoker (yes, no); alcohol 
dependence (yes, no); and drug dependence (yes, no).  
Dialysis center characteristics included in the analyses were, Ownership status of dialysis center 
(for-profit, non-profit, missing); the number of dialysis stations in a dialysis center (proxy for the 





Dialysis center assigned to a patient was extracted from Medicare claims as the center that patient 
received the most dialysis sessions at.  
Analysis 
Table 1 illustrates the descriptive statistics for all independent variables for all patients, and 
separately for patients who developed ESRD before and after PPS, to understand if the type of 
patients before and after the PPS were characteristically different. Table 2 descriptively illustrates 
cost of care for all patients and separately for patients who developed ESRD before and after PPS 
to understand it the unadjusted cost of care has changed after PPS compared with before PPS.  
 
Characteristics Associated with Cost of Care 
Interrupted time series analysis (ITSA) with ordinary least square (OLS) regressions were used to 
estimate the association between Time, PPS, and the interaction of Time and PPS with cost of care 
after controlling for patient and dialysis center characteristics. An ITSA with logistic regression 
was also used to estimate the association between these variables and having a non-zero inpatient 
cost. ITSA is a longitudinal study method widely used in public health and public policy research.27 
We used this method to estimate the change over time (time trend), immediate change after policy 
change, and the effect of policy change on time trend. All cost variables were right-skewed. We 
used logarithmically transformed cost as dependent variable in the ordinary least square (OLS) 
regression. Less than 1% of observations had $0 as outpatient, outpatient dialysis, or outpatient 
non-dialysis cost. We added $1 to these dependent variables for each observation. About 25% of 
observations had $0 as inpatient cost; we used two-part model to first estimate the probability of 
having non-zero inpatient cost; then OLS regression of logarithmically transformed inpatient cost 





non-zero inpatient cost. We used bivariate analyses to select the variables that were significant at 
the level of P<=0.1 for the final inclusion in the multi-variable models. The Halvorsen Palmquist 
method was used to correct the marginal effects from the log-OLS regressions before presentation 
in Table 3 and Table 4.28  
 
Sensitivity analysis 
In April 2013 government’s mandatory payment reductions in the Medicare fee-for-service (FFS) 
program known as “sequestration” went into effect. 29 Based on this law, Medicare FFS claims 
with dates-of-service or dates-of-discharge on or after April 1, 2013, would incur a 2 percent 
reduction in Medicare payment. We performed sensitivity analysis by excluding patients with 
study initiation date in July 2012 and after to examine whether the results were sensitive to 
excluding these patients. A total of 273,397 patients were included in sensitivity analysis. All 
analyses were performed using SAS v. 9.4 (SAS Institute, Cary, NC). Figures are created using R 
version 3.3.2.  
 
Study Results 
Characteristics of patient population for pre- and post-Policy Change 
Of 415,025 patients, 50.29% (208,735) developed ESRD from 2006 to 2010 (pre-PPS) and 49.71% 
(206,290) from 2011 to 2015 (post-PPS) (Table 1). Patients in post-PPS group were slightly 
younger, more likely to be male, more likely to be non-Hispanic White, belonged to slightly more 
educated and higher income ZIP-code areas but were more likely to be unemployed, more likely 
to be dual eligible for Medicare and Medicaid, and more likely to have disability as their initial 





more likely to have nephrology care before ESRD onset, more likely to have hypertension and 
diabetes as primary cause of ESRD, more likely to have chronic conditions such as hypertension, 
diabetes, COPD, and disability, but less likely to have CVD compared with pre-PPS patients. 
These patients had higher average BMI, and slightly worse hemoglobin and glomerular filtration 
rate compared with pre-PPS patients. Behaviorally, these patients were less likely to be a current 
smoker and alcohol or drug dependent compared with pre-PPS group. Compared with pre-PPS, 
more patients in post-policy change group initiated dialysis at a for-profit dialysis center (Table 
1).  
Cost of are for ESRD patients from Medicare’s Perspective 
Table 2 represents the average total cost, total outpatient cost, outpatient dialysis cost, outpatient 
non-dialysis, inpatient cost (with and without zero values), and proportion of patients with non-
zero inpatient cost for all patients, pre-PPS, and post-PPS patient groups. For all cost categories, 
the average cost was lower for post-PPS group compared with pre-policy change group. The 
highest difference belonged to total cost category ($109,167 vs. $100,742) and the lowest 
difference to outpatient dialysis cost ($27,430 vs. $26,063). After PPS, patients were less likely to 
have non-zero inpatient cost.  
 
Multiple regression examining characteristics associated with cost of care 
Four OLS regressions were performed with logarithmically transformed total cost, total outpatient 
cost, outpatient dialysis cost, and outpatient non-dialysis cost (Table 3). For inpatient care, we 
performed a logistic regression to examine characteristics associated with whether or not the 
patient had non-zero inpatient cost and an OLS with logarithmically transformed inpatient care 





OLS analysis in Table 3 and Table 4 are transformed to percentage change estimates using 
100*(𝑒(𝛽𝑥𝑖  ∗𝑥𝑖) − 1) formula.  
Changes in cost at time (t) compared with cost in Time=0 was calculated using these results and 
is visualized in figures 1a-1e. X-axis represents time and Y-axis represents percentage change 
compared with Time 0 for each cost category calculated by the following formula: 
Overall estimate at time=t compared with time=0: 100 × (𝑒(𝛽𝑡𝑖𝑚𝑒 ∗ 𝑡+ 𝛽𝑃𝑃𝑆 ∗ 𝑃𝑃𝑆+ 𝛽𝑡𝑖𝑚𝑒∗𝑃𝑃𝑆 ∗ 𝑡) − 1) 
Immediate change in cost after PPS is calculated by difference between overall association of time 
at t=10 and t=9. 
Before PPS, time was not significantly associated with total cost: 0.04% [95% CI: (-0.05, 0.13)],  
however, after PPS time was associated with lower total cost: -0.88% [95% CI: (-0.96, -0.79)]. 
There was also an immediate change -1.20% in total cost after PPS. (Figure 1a). Before PPS, time 
was associated with lower total outpatient and outpatient dialysis cost: -0.52% [95% CI: (-0.58, -
0.45)] and –0.92% [95% CI: (-1.03, -0.82)], respectively. Even though after PPS, the direction of 
the association remained the same for both cost categories, PPS was associated with immediate 
jump in cost, 4.21% for outpatient and 13.00% for outpatient dialysis cost. (Figure 1b, Figure 1c). 
before PPS, time was not significantly associated with outpatient non-dialysis cost before PPS. 
However, with a significant immediate drop in after PPS (11.33%), time was associated with 
higher outpatient non-dialysis cost after PPS: 1.38% [95% CI: (1.25, 1.51)]. (Figure 1d) 
Before PPS, time was associated with higher inpatient cost before PPS: 1.88% [95% CI: (1.7,1 
2.004]. PPS resulted in a significant immediate drop in inpatient cost (8.38%); after PPS, time was 
associated with lower inpatient cost: -2.50% [95% CI: (-2.73, -2.27)]. (Figure 1e) Before PPS, 





time was associated with lower odds of having non-zero inpatient cost as well. Figure 1f shows 
the predicted probability of having a non-zero cost from the logistic regression over time.  
Overall, age was associated with higher cost of care (all cost categories) and higher likelihood of 
having nonzero inpatient cost. Females compared with males, and  non-Hispanic Blacks compared 
with non-Hispanic whites had higher cost of care (except for outpatient dialysis cost) and higher 
likelihood of having non-zero inpatient cost. Hispanic or patients from other racial-ethnic groups 
however, had lower cost of care lower odds of having a non-zero inpatient cost. Patients who were 
dually eligible for Medicare and Medicaid had higher cost compared to non-dually eligible 
patients. Overall , patients who were initially eligible for Medicare due to reasons other that ESRD 
had higher cost of care and odds of having non-zero inpatient cost. Having nephrology care prior 
to ESRD onset was associated with lower cost of care (except for outpatient dialysis cost) and 
lower odds of having inpatient cost; for outpatient dialysis cost, it was associated with higher cost. 
Having chronic conditions such as diabetes, CVD, cancer, COPD, and disability, but not 
hypertension was overall associated with higher cost of care and higher odds of having inpatient 
cost. BMI was associated with increased cost of care. Being a current smoker or alcohol dependent 
was associated with lower cost of care; however, alcohol dependence was associated with higher 
inpatient cost and higher odds of having non-zero inpatient cost. Drug dependence was associated 
with higher total cost and inpatient cost and higher odds of having non-zero inpatient cost. patient 
who received most of their dialysis sessions at a for-profit dialysis center, had higher cost of care 








In this study, we explored the effect of Medicare reimbursement policy change for dialysis 
services, which was implemented in January 2011, on Medicare’s expenditure of providing care 
during one-year for ESRD patients who recently developed ESRD. This study found that while 
before PPS time was not associated with total cost, after PPS it was associated with declining cost. 
association of time and PPS with other cost categories differed from total cost. Adjusted total 
outpatient cost and outpatient dialysis cost had a declining trend before PPS; for both of the 
categories cost of care had an immediate increase after PPS but the declining trend continued after 
PPS. Outpatient non-dialysis cost continued to increase after an immediate drop in cost after PPS. 
On the other hand, increasing inpatient care cost had an immediate decline after PPS and declined 
afterwards. Probability of having a nonzero inpatient cost continued to decline after an immediate 
decrease after PPS.  
Results from the sensitivity analysis were similar for total cost, outpatient non-dialysis, inpatient 
cost and probability of having a non-zero inpatient cost. For outpatient and outpatient dialysis cost, 
the results showed an immediate increase in both cost categories (similar to original model), 
however after PPS cost increased by time. Figures 4a-4f visualize the change over time for cost 
category from sensitivity analysis.   
Medicare’s ESRD program started in 1973, ever since its ESRD program’s cost continued to grow 
both due to increase number of ESRD incidents and increase cost of care per patient. In 2017, 
ESRD prevalence in the US was 746,557 which compared to 2016 increased by 2.5%. Medicare’s 
expenditure also increased by 1.3% in 2017 compared with 2016. CMS has implemented multiple 
policies over years to contain the ESRD cost, In January 2011 CMS implemented PPS to contain 





dialysis session. Previous studies have explored dialysis center’s response to the bundled payment. 
After the policy change, dialysis centers have shifted towards replacing utilization of expensive 
drugs with less expensive ones. For example, research shows shift from utilizing ESA to IV iron 
or blood transfusion both in inpatient and outpatient setting;12–15 there was also a significant shift 
from intravenous vitamin D use to oral vitamin use and from more expensive paricalcitol towards 
a less expensive type, doxercalciferol.9,16 Use of antibiotics, levocarnitine, and alteplase has 
declined and utilization of cinacalcet and phosphate binders has increased.16 However, the effect 
of the PPS on Medicare’s cost of care has not been well studied. Every year USRDS releases an 
“Annual Data Report” which provides information on Medicare’s ESRD population and its 
expenditure.30 Expenditures presented in these reports are not adjusted for patient characteristics, 
geographic factors, and inflation. However, it provides a perspective of Medicare’s expenditure 
for the whole population over years, and categorized by age, gender, and race ethnicity. Figure 2 
and Figure 3 show unadjusted versus adjusted for CPI total expenditure and unadjusted versus 
adjusted for CPI PPPY expenditure calculated from USRDS annual data report 2019, respectively. 
Even though all these costs are unadjusted for patient characteristics and they include all ESRD 
patients regardless of the inclusion and exclusion criteria listed in the paper, total and PPPY 
expenditure adjusted for CPI show a declining cost after 2011 which supports our findings. 
USRDS report shows that Medicare’s PPPY expenditure increases by age; females have higher 
cost compared with males; non-Hispanic blacks have higher expenditure compared with non-
Hispanic whites, but Hispanic patients have lower cost compared with non-Hispanics. Patients 
with hypertension, glomerulonephritis, polycystic kidney disease, or other reasons as primary 
reason of ESRD have lower cost of care compared with patients with diabetes as their primary 





Our study has some limitations. First, our findings are not generalizable to all ESRD population 
and facilities, we have excluded prevalent patients, and patients who died or received a transplant 
during the first year. Second, based on “sequestration” law that went into effect on April 201329 
government mandated 2% reduction in payments for Medicare fee-for-service (FFS) services. 
Estimates in our model might have been influenced with this policy change and evolving CMS 
payment policies. To address this issue, we performed a sensitivity analysis and results remained 
very close to the original estimates for all cost categories other than dialysis and outpatient non-
dialysis cost. Third, the data did not have information on patient-level education and income which 
might be associated with cost of care and chance of hospitalization. These associations can 
confound the adjusted effects estimated in this study. However, this study used the U.S. Census 
data to control for the zip code-level income and education levels, which have been shown to be 
consistent proxies of personal socio-economic status.19, 20 Irrespective of the limitations, it is 
important to understand that the USRDS is a highly reliable population-based nationally 
representative dataset with high quality Medicare claims data, clinical, socio-demographic, and 
dialysis center level information.31,32  
In conclusion, this study found that Medicare’s policy PPS reduced the cost of care from 
Medicare’s perspective. It also showed that policy changes in dialysis payment could also 
influence the cost of care in other settings such as inpatient. The findings of this study showed that 
bundle payment policies have a potential to reduce cost of care, however clinical outcome of such 
policies need to be studied as well. 
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Table 1 Descriptive Statistics Illustrating the Patient, Dialysis Center, and Other Characteristics 










Patient Socio-Demographic Characteristics 
Age at study initiation (years) 63.99 (14.74) ┼ 64.08 (14.90) 63.90 (14.59) ┼ <0.0001 
Gender (%)     
Male 55.32 54.92 55.72 <0.0001 
Female  44.68 45.08 44.28  
Race-ethnicity (%)     
Non-Hispanic White 52.00 51.77 52.24 <0.0001 
Non-Hispanic Black 28.68 29.50 27.83  
Hispanic 14.17 13.89 14.46  
Non-Hispanic other 5.15 4.84 5.47  
Education (percent some college & above in ZIP code area) 47.12 (15.23) ┼ 47.07 (15.25) ┼ 47.16 (15.20) ┼ 0.01 
Income (median household income in ZIP code area – USD) 49,416 (19,964) ┼ 49,033 (19,831) ┼ 49,805 (20,091) ┼ <0.0001 
Employment status at study initiation (%)     
Unemployed 26.80 25.81 27.81 <0.0001 
Employed 4.98 4.89 5.07  
Retired due to age 42.61 43.39 41.84  
Retired due to disability 23.91 24.06 23.76  
Other 1.68 1.85 1.52  
Medicare and Medicaid Dual Eligibility     
Never dual eligible  52.61 53.48 51.72 <0.0001 
Partially dual eligible 12.23 11.90 12.57  
Always dual eligible 35.16 34.62 35.71  
Initial Medicare Eligibility Reason     
ESRD 31.47 31.30 31.63 <0.0001 
Age 52.58 53.40 51.77  
Disability 9.25 7.78 10.73  
Other 6.70 7.52 5.87  
Number of days from first ESRD service to study initiation 
date 19.81 20.09 19.54 
0.08 
Patient Clinical Characteristics 
Nephrology care prior to ESRD onset (%)     
Yes 62.09 60.71 63.51 <0.0001 
No 26.38 28.28 24.45  
Missing 11.53 11.01 12.04  
Primary cause of ESRD (%)     
Diabetes 48.66 48.34 49.00 <0.0001 
Hypertension 31.10 30.51 31.70  
Glomerulonephritis 7.23 7.52 6.93  
Polycystic kidney disease 1.74 1.76 1.72  
Other 11.27 11.88 10.65  
Presence of hypertension at study initiation (%)     
Yes 88.37 87.43 89.32 <0.0001 
No 11.63 12.57 10.68  
Presence of diabetes at study initiation (%)     
Yes 57.65 56.24 59.07 <0.0001 
No 42.35 43.76 40.93  
Presence of CVD* at study initiation (%)     
Yes 53.87 55.63 52.09 <0.0001 
No 46.13 44.37 47.91  
Presence of cancer at study initiation (%)     
Yes 6.53 6.60 6.46 0.056 
No 93.47 93.40 93.54  
Presence of COPD at study initiation (%)     
Yes 9.14 9.02 9.26 0.009 
No 90.86 90.98 90.74  
Presence of Disability at study initiation (%)     
Yes 17.13 16.58 17.68 <0.0001 
No 82.87 83.42 82.32  
BMI at study initiation (continuous) 29.56 (7.95) ┼ 29.30 (7.89) ┼ 29.83 (8.00) ┼ <0.0001 
GFR EPI at study initiation (continuous) 9.46 (5.24) ┼ 9.50 (5.33) ┼ 9.42 (5.15) ┼ 0.005 
GFR MDRD at study initiation (continuous) 10.11 (4.51) ┼ 10.16 (4.54) ┼ 10.07 (4.48) ┼ <0.0001 
Hemoglobin at study initiation (continuous) 10.08 (19.56) ┼ 10.45 (25.07) ┼ 9.70 (11.54) ┼ <0.0001 














Current smoker at study initiation (%)     
Yes 6.64 6.72 6.56 0.04 
No 93.36 93.28 93.44  
Alcohol dependence at study initiation (%)     
Yes 1.28 1.35 1.22 0.0002 
No 98.72 98.65 98.78  
Drug dependence at study initiation (%)     
Yes 1.14 1.26 1.02 <0.0001 
No 98.86 98.74 98.98  
Dialysis Center Characteristics 
Ownership Status     
For-profit 82.70 80.25 85.18 <0.0001 
Non-profit 13.61 15.99 11.20  
Missing 3.69 3.76 3.63  
Number of dialysis stations (count) 16.27 (2.99) ┼ 16.24 (2.87) ┼ 16.30 (3.11) ┼ <0.0001 
ESRD Network (%)     
• Network 1 (CT, ME, MA, NH, RI, VT) 3.58 3.66 3.50 <0.0001 
• Network 2 (NY) 5.34 5.49 5.18  
• Network 3 (NJ, PR, VI) 4.33 4.38 4.29  
• Network 4 (DE, PA) 3.80 3.84 3.76  
• Network 5 (DC, MD, VA, WV) 5.97 5.90 6.05  
• Network 6 (GA, NC, SC) 9.95 9.97 9.93  
• Network 7 (FL) 6.27 6.25 6.29  
• Network 8 (AL, MS, TN) 6.14 6.04 6.24  
• Network 9 (IN, KY, OH) 7.59 7.76 7.41  
• Network 10 (IL) 4.49 4.46 4.53  
• Network 11 (MI, MN, ND, SD, WI) 6.55 6.82 6.27  
• Network 12 (IA, KS, MO, NE) 4.20 4.25 4.15  
• Network 13 (AR, LA, OK) 4.77 4.77 4.78  
• Network 14 (TX) 9.69 9.69 9.67  
• Network 15 (AZ, CO, NV, NM, UT, WY)  4.24 4.09 4.40  
• Network 16 (AK, ID, MT, OR, WA) 2.92 2.86 2.98  
• Network 17 (AS, Guam, HI, Mariana Islands, 
Northern CA)  4.04 3.86 4.22 
 
• Network 18 (Southern CA) 6.13 5.92 6.35  
 
Note: *CVD: atherosclerotic heart disease, congestive heart failure, peripheral vascular disease, cerebrovascular disease, and other cardiac 
problem  
                ┼ Mean with standard deviation in parenthesis presented for continuous variables 
          Abbreviations: ESRD - End-Stage Renal Disease; CVD - Cardiovascular Disease; COPD - Chronic Obstructive Pulmonary Disease; BMI - 
Body Mass Index; GFR EPI - Glomerular Filtration Rate Epidemiology Collaboration; GFR MDRD - Glomerular Filtration Rate Modification of 



















Total Cost of Care* 104,980 (70,658) 109,167 (73,568) 100,742 (67,321) <0.0001 
Outpatient Care Cost* 62,636 (26,051) 64,255 (27,701) 60,998 (24,157) <0.0001 
Outpatient Dialysis Care Cost* 35,886 (9,951) 36,825 (11,354) 34,935 (8,185) <0.0001 
Outpatient Non-Dialysis Care Cost* 26,750 (23,781) 27,430 (24,111) 26,063 (23,423) <0.0001 
Inpatient Care Cost (With Zero Values) * 42,192 (56,090) 44,745 (57,5561) 39,609 (54,444) <0.0001 
Inpatient Care Cost (Without Zero Values) * 56,435 (58,347) 57,558 (59,362) 55,203 (57,187) <0.0001 
Non-zero Inpatient Cost (%) 73.19 77.74 71.75 <0.0001 










Table 3 Effects of the Independent Variables on Medicare’s 1-Year Cost of Care  





Dialysis Care Cost 
Time during Pre-PPS 0.04 (-0.05, 0.13) -0.52 (-0.58, -0.45) ** -0.92 (-1.03, -0.82) ** 0.13 (-0.01, 0.26) 
PPS (Reference: Pre-PPS)     
Post-PPS -1.20 (-1.91, -0.49) ** 4.21 (3.65, 4.77) ** 13.00 (12.06, 13.95) ** -11.33 (-12.27, -10.39) ** 
Time during Post-PPS -0.88 (-0.96, -0.79) ** -0.80 (-0.87, -0.74) ** -1.41 (-1.51, -1.31) ** 1.38 (1.25, 1.51) ** 
Patient Socio-Demographic Characteristics     
Age at study initiation -0.84 (-0.92, -0.76) ** -0.73 (-0.79, -0.67) ** -1.58 (-1.67, -1.48) ** 0.77 (0.65, 0.9) ** 
Age at study initiation- squared 0.01 (0.01, 0.01) ** 0.01 (0.01, 0.01) ** 0.01 (0.01, 0.01) ** 0.01 (0.01, 0.01) ** 
Gender (Reference: Male)     
Female 5.47 (5.08, 5.87) ** 1.63 (1.35, 1.92) ** -1.07 (-1.5, -0.64) ** 11.44 (10.83, 12.05) ** 
Race-ethnicity (Reference: Non-Hispanic White)     
Non-Hispanic Black 2.07 (1.58, 2.56) ** 0.93 (0.57, 1.29) ** -0.87 (-1.43, -0.32) ** 1.53 (0.81, 2.25) ** 
Hispanic -4.29 (-4.89, -3.68) ** -2.88 (-3.34, -2.42) ** -1.6 (-2.32, -0.87) ** -6.70 (-7.57, -5.83) ** 
Non-Hispanic Other -9.70 (-10.49, -8.90) ** -7.27 (-7.88, -6.66) ** -2.55 (-3.54, -1.54) ** -16.29 (-17.37, -15.19) ** 
Education  0.04 (0.03, 0.06) ** 0.02 (0.01, 0.03) ** 0.00 (-0.01, 0.02) 0.02 (0.00, 0.04) 
Logarithm of Income -2.25 (-2.81, -1.70) ** -1.19 (-1.61, -0.77) ** -0.04 (-0.69, 0.63) -0.32 (-1.15, 0.52) 
Employment status at study initiation (Reference: Unemployed)     
 
Employed -11.04 (-11.82, -10.25) ** -6.16 (-6.78, -5.54) ** -1.12 (-2.13, -0.1) ** -17.97 (-19.03, -16.9) ** 
Retired due to age 1.41 (0.83, 2.00) ** 1.24 (0.80, 1.67) ** 1.30 (0.62, 1.98) ** 1.38 (0.52, 2.24) ** 
Retired due to disability 3.13 (2.58, 3.68) ** 1.94 (1.54, 2.34) ** -1.72 (-2.32, -1.11) ** 6.98 (6.15, 7.82) ** 
Other -8.92 (-10.21, -7.61) ** -5.73 (-6.73, -4.72) ** -5.48 (-7.04, -3.9) ** -11.96 (-13.79, -10.10) ** 
Medicare and Medicaid Dual Eligibility (Reference: Never dual eligible)     
Always dual eligible 11.40 (10.71, 12.10) 5.20 (4.71, 5.69) ** 3.14 (2.4, 3.89) ** 13.97 (12.94, 15.02) ** 
Partially dual eligible 11.78 (11.27, 12.30) ** 7.37 (7.00, 7.74) ** 5.19 (4.63, 5.75) ** 19.63 (18.82, 20.44) ** 
Initial Medicare Eligibility Reason (Reference: ESRD)     
Age 9.45 (8.70, 10.21) ** 6.53 (5.99, 7.08) ** 2.46 (1.64, 3.28) ** 17.72 (16.53, 18.91) ** 
Disability 16.47 (15.57, 17.39) ** 8.06 (7.43, 8.69) ** -0.95 (-1.84, -0.05) * 27.57 (26.11, 29.04) ** 
Other 3.16 (2.28, 4.04) ** 2.47 (1.82, 3.12) ** -1.41 (-2.38, -0.43) ** 9.17 (7.80, 10.54) ** 
Number of days from first ESRD service to study initiation date -0.30 (-0.31, -0.29) ** -0.14 (-0.15, -0.14) ** -0.11 (-0.12, -0.10) ** -0.23 (-0.24, -0.22) ** 
 
Patient Clinical Characteristics 
    
Nephrology care prior to study initiation (Reference: No)     
Yes -13.64 (-14.01, -13.26) ** -4.13 (-4.44, -3.82) ** 5.60 (5.07, 6.13) ** -18.1 (-18.62, -17.58) ** 
Missing  1.30 (0.65, 1.95) ** 0.29 (-0.18, 0.77) ** -1.39 (-2.12, -0.66) ** 0.09 (-0.85, 1.03) 
Primary cause of ESRD (Reference: Diabetes)     
Hypertension -4.63 (-5.13, -4.13) ** -3.70 (-4.07, -3.32) ** -0.91 (-1.5, -0.30) ** -9.25 (-9.95, -8.55) ** 
Glomerulonephritis -5.40 (-6.16, -4.63) ** -4.92 (-5.49, -4.34) ** -2.84 (-3.75, -1.92) ** -12.16 (-13.2, -11.11) ** 
Polycystic kidney disease -14.91 (-16.12, -13.69) ** -8.46 (-9.43, -7.48) ** 0.42 (-1.24, 2.11) -26.31 (-27.85, -24.73) ** 
Other 3.46 (2.75, 4.17) ** -0.97 (-1.47, -0.46) ** -7.18 (-7.91, -6.44) ** 4.27 (3.22, 5.32) ** 
Presence of hypertension at study initiation (Reference: No)     
Yes -3.63 (-4.18, -3.09) ** -1.37 (-1.79, -0.95) ** 1.82 (1.15, 2.49) ** -5.83 (-6.61, -5.05) ** 
Presence of diabetes at study initiation (Reference: No)     
Yes 6.28 (5.76, 6.81) ** 3.85 (3.47, 4.24) ** -0.11 (-0.68, 0.46) 12.85 (12.03, 13.67) ** 
Presence of CVD at study initiation (Reference: No)     
Yes 10.96 (10.53, 11.39) ** 4.57 (4.27, 4.87) ** 0.34 (-0.11, 0.80) 14.11 (13.46, 14.76) ** 
Presence of Cancer at study initiation (Reference: No)     










Dialysis Care Cost 
Presence of COPD at study initiation (Reference: No)     
Yes 8.06 (7.37, 8.75) ** 3.10 (2.60, 3.59) ** -1.17 (-1.91, -0.43) ** 9.82 (8.79, 10.86) ** 
Presence of Disability at study initiation (Reference: No)     
Yes 25.23 (24.62, 25.85) ** 12.24 (11.83, 12.66) ** -3.43 (-3.98, -2.88) ** 33.8 (32.84, 34.78) ** 
BMI at study initiation -0.48 (-0.6, -0.36) ** 0.41 (0.32, 0.50) ** 1.11 (0.96, 1.25) ** -0.74 (-0.92, -0.56) ** 
BMI at study initiation Squared 0.01 (0.01, 0.01) ** 0.01 (0.00, 0.02) * -0.01 (-0.01, -0.01) ** 0.02 (0.01, 0.02) ** 
GFR EPI at study initiation 0.53 (0.47, 0.59) ** 0.07 (0.02, 0.11) ** -0.48 (-0.55, -0.42) ** 0.70 (0.61, 0.79) ** 
GFR MDRD at study initiation 0.39 (0.32, 0.46) ** 0.24 (0.19, 0.29) ** -0.05 (-0.13, 0.03) 0.83 (0.73, 0.93) ** 
Hemoglobin at study initiation -0.02 (-0.02, -0.01) ** -0.01 (-0.02, -0.01) ** -0.01 (-0.01, 0.00) -0.02 (-0.03, -0.01) ** 
Patient Behavioral Characteristics     
Current Smoker at study initiation (Reference: No)     
Yes -3.85 (-4.57, -3.13) ** -4.11 (-4.65, -3.57) ** -3.37 (-4.21, -2.53) ** -4.76 (-5.81, -3.71) ** 
Alcohol dependent at study initiation (Reference: No)     
Yes -1.39 (-3.00, 0.25) -3.78 (-4.95, -2.59) ** -7.13 (-8.89, -5.34) ** -0.89 (-3.27, 1.54) 
Drug dependent at study initiation (Reference: No)     
Yes 7.15 (5.29, 9.05) ** -4.60 (-5.84, -3.35) ** -10.41 (-12.22, -8.56) ** 3.37 (0.75, 6.05) * 
Dialysis Center Characteristics     
Ownership status (Reference: Non-profit)     
For-profit 5.75 (5.17, 6.33) ** 5.04 (4.62, 5.47) ** 4.58 (3.92, 5.25) ** 6.57 (5.72, 7.42) ** 
Missing -16.66 (-17.54, -15.79) ** -24.39 (-24.98, -23.8) ** -61.76 (-62.23, -61.29) ** -11.99 (-13.34, -10.62) ** 
Number of dialysis stations 0.09 (0.03, 0.15) ** 0.05 (0.01, 0.09) * 0.09 (0.02, 0.16) ** 0.02 (-0.06, 0.11) 
Network (Reference: Network 6 - GA, NC, SC)     
         Network 1 (CT, ME, MA, NH, RI, VT) -0.06 (-1.19, 1.07)  -6.97 (-7.76, -6.19) ** -5.85 (-7.08, -4.60) ** -1.73 (-3.36, -0.09) * 
         Network 2 (NY) 1.87 (0.86, 2.88) ** -7.96 (-8.64, -7.28) ** -5.87 (-6.95, -4.78) ** -2.44 (-3.85, -1.00) ** 
         Network 3 (NJ, PR, VI) 3.37 (2.27, 4.47) ** -0.75 (-1.53, 0.04) -4.72 (-5.88, -3.53) ** 7.91 (6.24, 9.60) ** 
         Network 4 (DE, PA) 3.00 (1.89, 4.14) ** -2.83 (-3.62, -2.03) ** -3.57 (-4.79, -2.34) ** 2.41 (0.78, 4.07) ** 
         Network 5 (DC, MD, VA, WV) -1.39 (-2.31, -0.46) ** -7.58 (-8.22, -6.93) ** -7.73 (-8.73, -6.71) ** -4.29 (-5.6, -2.95) ** 
         Network 7 (FL) 3.09 (2.14, 4.04) ** -2.01 (-2.68, -1.33) ** -5.53 (-6.54, -4.51) ** 7.28 (5.83, 8.75) ** 
         Network 8 (AL, MS, TN) -1.1 (-2.01, -0.19) * 0.08 (-0.61, 0.77) 2.27 (1.17, 3.37) ** -1.95 (-3.27, -0.61) ** 
         Network 9 (IN, KY, OH) 1.13 (0.24, 2.02) * -1.09 (-1.74, -0.44) ** 0.93 (-0.10, 1.97) -1.15 (-2.42, 0.13) 
         Network 10 (IL) -1.90 (-2.91, -0.88) ** -3.61 (-4.35, -2.87) ** -1.64 (-2.81, -0.45) ** -3.21 (-4.67, -1.72) ** 
         Network 11 (MI, MN, ND, SD, WI) -0.38 (-1.29, 0.54) -1.77 (-2.45, -1.10) ** 4.81 (3.69, 5.94) ** -1.57 (-2.89, -0.22) * 
         Network 12 (IA, KS, MO, NE) -2.94 (-3.96, -1.90) ** -2.76 (-3.53, -1.99) ** 4.82 (3.54, 6.12) ** -5.52 (-6.98, -4.04) ** 
         Network 13 (AR, LA, OK) 0.80 (-0.21, 1.81) -1.47 (-2.20, -0.73) ** -0.59 (-1.74, 0.58) 1.21 (-0.27, 2.71) 
         Network 14 (TX) 6.83 (5.93, 7.75) ** 3.28 (2.63, 3.94) ** -2.22 (-3.18, -1.24) ** 15.28 (13.84, 16.74) ** 
         Network 15 (AZ, CO, NV, NM, UT, WY)  -5.95 (-6.95, -4.93) ** -7.56 (-8.30, -6.82) ** -4.21 (-5.40, -3.01) ** -9.97 (-11.38, -8.54) ** 
         Network 16 (AK, ID, MT, OR, WA) -11.53 (-12.6, -10.44) -8.34 (-9.17, -7.50) ** 1.94 (0.50, 3.40) ** -18.27 (-19.73, -16.79) ** 
         Network 17 (AS, Guam, HI, Mariana I, N. CA)  -10.42 (-11.41, -9.41) ** -10.05 (-10.79, -9.30) ** -1.76 (-3.03, -0.48) ** -23.52 (-24.76, -22.25) ** 
         Network 18 (Southern CA) -9.09 (-9.99, -8.18) ** -10.43 (-11.10, -9.77) ** -9.27 (-10.31, -8.22) ** -14.89 (-16.12, -13.64) ** 
N 415,025 415,025 415,025 415,025 
R2 0.16 0.11 0.09 0.16 
RMSE 0.59 0.44 0.68 0.86 
Note: * : Significant at P<0.05, ** : Significant at P<0.01 
          Abbreviations: ESRD - End-Stage Renal Disease; Cardiovascular Disease; COPD - Chronic Obstructive Pulmonary Disease; BMI - Body Mass Index; GFR EPI - Glomerular Filtration Rate 






Table 4 Effects of the Independent Variables on Medicare’s 1-Year Cost of inpatient care and 
chance of having non-zero inpatient cost  
Variable  OR: Non-zero inpatient cost Inpatient Cost 
Time during Pre-PPS 0.98 (0.98, 0.99) ** 1.88 (1.71, 2.04) ** 
PPS (Reference: Pre-PPS)    
Post-PPS 0.78 (0.76, 0.81) ** -8.38 (-9.61, -7.13) ** 
Time during Post-PPS 0.99 (0.99, 0.99) ** -0.73 (-0.89, -0.56) ** 
Patient Socio-Demographic Characteristics   
Age at study initiation 0.97 (0.96, 0.97) ** 0.11 (-0.05, 0.28) 
Age at study initiation- squared 1.01 (1.01, 1.01) ** -0.01 (-0.01, -0.01) ** 
Gender (Reference: Male)    
Female 1.25 (1.23, 1.27) ** 8.99 (8.23, 9.76) ** 
Race-ethnicity (Reference: Non-Hispanic White)    
Non-Hispanic Black 1.05 (1.03, 1.08) ** 1.87 (0.95, 2.79) ** 
Hispanic 0.93 (0.91, 0.96) ** -5.19 (-6.33, -4.03) ** 
Non-Hispanic Other 0.82 (0.80, 0.85) ** -8.19 (-9.78, -6.58) ** 
Education  1.00 (0.99, 1.01) 0.09 (0.07, 0.12) ** 
Logarithm of Income 1.02 (0.99, 1.04) -4.83 (-5.85, -3.80) ** 
Employment status at study initiation (Reference: 
Unemployed)   
 
 
Employed 0.75 (0.73, 0.78) ** -11.39 (-13.07, -9.67) ** 
Retired due to age 1.05 (1.02, 1.08) ** -0.64 (-1.70, 0.42) 
Retired due to disability 1.14 (1.11, 1.16) ** 1.27 (0.25, 2.29) * 
Other 0.81 (0.77, 0.85) ** -6.56 (-9.40, -3.62) ** 
Medicare and Medicaid Dual Eligibility (Reference: Never 
dual eligible)   
 
Always dual eligible 1.30 (1.26, 1.33) ** 18.92 (17.51, 20.35) ** 
Partially dual eligible 1.39 (1.36, 1.42) ** 11.64 (10.69, 12.60) ** 
Initial Medicare Eligibility Reason (Reference: ESRD)    
Age 1.27 (1.23, 1.30) ** 4.57 (3.20, 5.96) ** 
Disability 1.64 (1.58, 1.69) ** 14.91 (13.27, 16.58) ** 
Other 1.04 (1.01, 1.07) * 0.24 (-1.44, 1.95) 
Number of days from first ESRD service to study initiation 
date 0.99 (0.99, 0.99) ** -0.18 (-0.20, -0.17) ** 
 
Patient Clinical Characteristics 
  
Nephrology care prior to study initiation (Reference: No)   
Yes 0.57 (0.56, 0.58) ** -18.78 (-19.43, -18.13) ** 
Missing  1.05 (1.02, 1.08) ** 2.37 (1.18, 3.57) ** 
Primary cause of ESRD (Reference: Diabetes)    
Hypertension 0.86 (0.84, 0.88) ** -2.37 (-3.31, -1.42) ** 
Glomerulonephritis 0.86 (0.84, 0.89) ** -1.80 (-3.33, -0.25) * 
Polycystic kidney disease 0.59 (0.56, 0.63) ** -16.80 (-19.32, -14.2) ** 
Other 1.07 (1.03, 1.10) ** 10.56 (9.18, 11.96) ** 
Presence of hypertension at study initiation (Reference: No)    
Yes 0.90 (0.88, 0.92) ** -5.91 (-6.89, -4.92) 
Presence of diabetes at study initiation (Reference: No)    
Yes 1.23 (1.20, 1.25) ** 5.13 (4.17, 6.10) ** 
Presence of CVD at study initiation (Reference: No)    
Yes 1.50 (1.48, 1.53) ** 13.15 (12.32, 13.98) ** 
Presence of Cancer at study initiation (Reference: No)    
Yes 1.11 (1.07, 1.14) ** 0.87 (-0.47, 2.24) 
Presence of COPD at study initiation (Reference: No)    
Yes 1.46 (1.41, 1.51) ** 9.64 (8.40, 10.89) ** 
Presence of Disability at study initiation (Reference: No)    
Yes 1.79 (1.75, 1.83) ** 36.02 (34.84, 37.20) ** 
BMI at study initiation 0.96 (0.96, 0.97) ** -1.35 (-1.58, -1.13) ** 
BMI at study initiation Squared 1.01 (1.01, 1.01) ** 0.01 (0.01, 0.02) ** 
GFR EPI at study initiation 1.02 (1.01, 1.02) ** 0.98 (0.88, 1.09) ** 
GFR MDRD at study initiation 1.00 (0.99, 1.01) 0.74 (0.62, 0.87) ** 
Hemoglobin at study initiation 0.99 (0.99, 0.99) * 0.00 (-0.02, 0.01) 





Variable  OR: Non-zero inpatient cost Inpatient Cost 
Current Smoker at study initiation (Reference: No)   
Yes 1.01 (0.98, 1.04) -3.77 (-5.13, -2.38) ** 
Alcohol dependent at study initiation (Reference: No)    
Yes 1.12 (1.04, 1.20) ** 0.40 (-2.66, 3.56) 
Drug dependent at study initiation (Reference: No)    
Yes 1.47 (1.37, 1.58) * 19.58 (15.7, 23.58) ** 
Dialysis Center Characteristics   
Ownership status (Reference: Non-profit)   
For-profit 1.17 (1.14, 1.20) ** 2.42 (1.36, 3.49) ** 
Missing 1.05 (1.01, 1.10) * -6.36 (-8.21, -4.47) ** 
Number of dialysis stations 1.01 (1.01, 1.01) ** 0.09 (-0.03, 0.21) 
Network (Reference: Network 6 - GA, NC, SC)   
         Network 1 (CT, ME, MA, NH, RI, VT) 1.18 (1.12, 1.23) ** 13.45 (11.10, 15.86) ** 
         Network 2 (NY) 1.21 (1.16, 1.26) ** 20.08 (17.87, 22.33) ** 
         Network 3 (NJ, PR, VI) 1.23 (1.18, 1.29) ** 8.27 (6.15, 10.44) ** 
         Network 4 (DE, PA) 1.20 (1.14, 1.26) ** 12.14 (9.88, 14.45) ** 
         Network 5 (DC, MD, VA, WV) 1.14 (1.09, 1.18) ** 6.65 (4.79, 8.55) ** 
         Network 7 (FL) 1.42 (1.36, 1.48) ** 5.32 (3.52, 7.14) ** 
         Network 8 (AL, MS, TN) 0.99 (0.95, 1.03) -4.25 (-5.91, -2.55) ** 
         Network 9 (IN, KY, OH) 1.14 (1.10, 1.18) ** 3.33 (1.65, 5.04) ** 
         Network 10 (IL) 1.02 (0.98, 1.07) 2.14 (0.18, 4.14) * 
         Network 11 (MI, MN, ND, SD, WI) 1.01 (0.98, 1.05) 4.28 (2.49, 6.10) ** 
         Network 12 (IA, KS, MO, NE) 1.01 (0.97, 1.05) -4.65 (-6.54, -2.72) ** 
         Network 13 (AR, LA, OK) 1.07 (1.02, 1.11) ** 2.59 (0.67, 4.55) ** 
         Network 14 (TX) 1.18 (1.14, 1.23) ** 9.78 (8.02, 11.56) ** 
         Network 15 (AZ, CO, NV, NM, UT, WY)  0.94 (0.90, 0.98) ** -0.38 (-2.43, 1.71)  
         Network 16 (AK, ID, MT, OR, WA) 0.73 (0.69, 0.76) ** -12.01 (-14.11, -9.87) ** 
         Network 17 (AS, Guam, HI, Mariana I, N. CA)  0.70 (0.67, 0.74) ** -1.60 (-3.71, 0.57) 
         Network 18 (Southern CA) 0.78 (0.75, 0.81) ** 4.71 (2.73, 6.73) ** 
N 415,025 310,284 
R2 - 0.07 
RMSE - 0.95 
Note: * : Significant at P<0.05, ** : Significant at P<0.01 
          Abbreviations: ESRD - End-Stage Renal Disease; Cardiovascular Disease; COPD - Chronic Obstructive Pulmonary Disease; BMI - 
Body Mass Index; GFR EPI - Glomerular Filtration Rate Epidemiology Collaboration; GFR MDRD - Glomerular Filtration Rate 


















Figure 1c: Outpatient Dialysis Cost 
 
 






Figure 1e: Inpatient Cost 
 
 































Figure 4c: Sensitivity Analysis – Outpatient Dialysis Cost 
 
 



















This study found that informing patients about kidney transplantation options is 
associated with increased odds of patients deciding to enroll in WL or receiving an LDKT. 
However, the effect of informing patients was less pronounced in for-profit dialysis centers 
compared with non-profit dialysis centers. Patient characteristics did not explain the observed 
difference, and the type of patients being informed was similar between for-profit and non-
profit dialysis centers. Also, patients in for-profit dialysis centers had higher odds of being 
informed about transplantation options compared with patients in non-profit dialysis centers. 
Therefore, this study showed that information provided by for-profit dialysis centers was less 
effective and potentially lower quality than that provided by non-profit dialysis centers.   The 
study highlights the need for developing guidelines to standardize transplantation information 
provided, in order to ensure similar informational quality across centers.  
This study also showed that Medicare’s PPS which was implemented in 2011 was 
associated with reduced total cost of 1-year care for new ESRD patients who received regular 
dialysis. However, the effect was not the same for all cost subcategories. Total outpatient and 
outpatient dialysis costs had declining trends over time before PPS.  However, both cost 
categories had a significant increase right after PPS and the cost continued to decrease at a 
higher rate afterwards. Outpatient non-dialysis had an increasing trend over time before PPS; 
this category had a significant decrease immediately after PPS but continued to increase at a 
higher rate afterwards. Inpatient cost was growing before PPS, but the estimated cost 
significantly dropped right after PPS and started to decline afterwards.  Probability of having 





significantly after PPS. Hence, the study found that the PPS was associated with decreasing 
total cost of care. However, the effect was not the same for all cost subcategories. Nevertheless, 






Appendix: Table 1 -Sensitivity Analysis- Adjusted Odds Ratios Demonstrating the Effect of 
Patient, Dialysis Center, and Other Characteristics on Transplantation Status 
 WL enrolled  
OR Estimate (95% CI) 
(Reference: Remaining on dialysis) 
LDKT received 
OR Estimate (95% CI) 
(Reference: Remaining on dialysis) 
Informed versus Uninformed Comparison:   
For For-profit 1.55 (1.49, 1.61)** 2.16 (1.90, 2.45)** 
For Non-Profit 1.85 (1.69, 2.01)** 2.70 (2.05, 3.56)** 
Patient Socio-Demographic Characteristics   
Age at study initiation 0.97 (0.97, 0.97)** 0.94 (0.94, 0.94)** 
Gender (Reference: Male)   
Female 0.82 (0.80, 0.84)** 0.78 (0.74, 0.82)** 
Race-ethnicity (Reference: Non-Hispanic White)   
Non-Hispanic Black 0.77 (0.75, 0.79)** 0.22 (0.20, 0.24)** 
Hispanic 1.04 (1.01, 1.07)** 0.67 (0.62, 0.72)** 
Non-Hispanic Other 1.09 (1.04, 1.13)** 0.38 (0.34, 0.42)** 
Education  1.01 (1.01, 1.01)** 1.01 (1.01, 1.01)** 
Logarithm of Income 1.52 (1.47, 1.57)** 2.46 (2.26, 2.66)** 
Employment status at study initiation (Reference: Unemployed)   
 
Employed 1.63 (1.59, 1.67)** 2.45 (2.29, 2.63)** 
Retired due to age 1.29 (1.24, 1.35)** 1.71 (1.50, 1.95)** 
Retired due to disability 1.07 (1.04, 1.10)** 1.07 (0.98, 1.17) 
Other 1.34 (1.29, 1.39)** 1.79 (1.64, 1.96)** 
Insurance at study initiation (Reference: Medicare)   
Medicaid 0.88 (0.86, 0.91)** 0.74 (0.67, 0.82)** 
Private insurance 1.77 (1.73, 1.82)** 2.89 (2.68, 3.11)** 
Other 1.28 (1.23, 1.32)** 2.05 (1.86, 2.25)** 
Uninsured 0.45 (0.40, 0.51)** 0.40 (0.27, 0.59)** 
 
Patient Clinical Characteristics   
Nephrology care prior to study initiation (Reference: No)   
Yes 1.77 (1.73, 1.81)** 2.02 (1.90, 2.14)** 
Missing  1.10 (1.06, 1.14)** 1.12 (1.01, 1.24)* 
Primary cause of ESRD (Reference: Diabetes)   
Hypertension 0.99 (0.96, 1.02) 1.14 (1.04, 1.26)** 
Glomerulonephritis 1.34 (1.30, 1.39)** 2.21 (2.01, 2.43)** 
Polycystic kidney disease 1.75 (1.66, 1.84)** 2.13 (1.88, 2.41)** 
Other 0.78 (0.75, 0.81)** 1.05 (0.94, 1.16) 
Presence of hypertension at study initiation (Reference: No)   
Yes 1.18 (1.15, 1.21)** 1.13 (1.05, 1.21)** 
Presence of diabetes at study initiation (Reference: No)   
Yes 0.95 (0.93, 0.98)** 0.74 (0.68, 0.81)** 
Presence of CVD at study initiation (Reference: No)   
Yes 0.67 (0.66, 0.69)** 0.61 (0.57, 0.65)** 
Presence of Cancer at study initiation (Reference: No)   
Yes 0.47 (0.44, 0.50)** 0.45 (0.38, 0.53)** 
Presence of COPD at study initiation (Reference: No)   
Yes 0.55 (0.52, 0.58)** 0.45 (0.36, 0.57)** 
Presence of Disability at study initiation (Reference: No)   
Yes 0.47 (0.45, 0.49)** 0.38 (0.32, 0.45)** 
BMI at study initiation 0.97 (0.97, 0.97)** 0.95 (0.94, 0.95)** 
GFR EPI at study initiation 0.98 (0.98, 0.99)** 0.98 (0.97, 0.99)** 
GFR MDRD at study initiation 0.99 (0.99, 0.99)** 0.98 (0.97, 0.99)** 
Patient Behavioral Characteristics   
Current smoker at study initiation (Reference: No)   
Yes 0.51 (0.49, 0.53)** 0.42 (0.37, 0.47)** 
Alcohol dependent at study initiation (Reference: No)   





 WL enrolled  
OR Estimate (95% CI) 
(Reference: Remaining on dialysis) 
LDKT received 
OR Estimate (95% CI) 
(Reference: Remaining on dialysis) 
Drug dependent at study initiation (Reference: No)   
Yes 0.27 (0.24, 0.30)** 0.24 (0.16, 0.36)** 
Dialysis Center Characteristics   
Number of dialysis stations 0.99 (0.99, 0.99)** 0.99 (0.99, 0.99)** 
Regional ESRD Network (Reference: Network 14 - TX)   
         Network 1 (CT, ME, MA, NH, RI, VT) 1.41 (1.28, 1.56)** 1.61 (1.36, 1.92)** 
         Network 2 (NY) 1.27 (1.17, 1.38)** 1.62 (1.38, 1.89)** 
         Network 3 (NJ, PR, VI) 1.05 (0.96, 1.15) 1.23 (1.04, 1.46)* 
         Network 4 (DE, PA) 1.49 (1.37, 1.62)** 1.35 (1.14, 1.60)* 
         Network 5 (DC, MD, VA, WV) 0.94 (0.87, 1.01) 1.10 (0.94, 1.29) 
         Network 6 (GA, NC, SC) 0.73 (0.68, 0.78)** 0.56 (0.48, 0.66)** 
         Network 7 (FL) 0.60 (0.55, 0.65)** 0.63 (0.53, 0.74)** 
         Network 8 (AL, MS, TN) 1.04 (0.96, 1.12) 1.04 (0.88, 1.23) 
         Network 9 (IN, KY, OH) 0.82 (0.76, 0.89)** 1.19 (1.03, 1.37)* 
         Network 10 (IL) 1.14 (1.05, 1.24)** 1.66 (1.41, 1.94)** 
         Network 11 (MI, MN, ND, SD, WI) 1.34 (1.24, 1.45)** 1.83 (1.58, 2.12)** 
         Network 12 (IA, KS, MO, NE) 0.93 (0.85, 1.02) 1.02 (0.86, 1.22) 
         Network 13 (AR, LA, OK) 0.72 (0.66, 0.79)** 0.68 (0.56, 0.83)** 
         Network 15 (AZ, CO, NV, NM, UT, WY)  0.88 (0.81, 0.95)** 1.03 (0.88, 1.20) 
         Network 16 (AK, ID, MT, OR, WA) 0.70 (0.63, 0.77)** 0.75 (0.62, 0.91)** 
         Network 17 (AS, Guam, HI, Mariana I, N. CA)  1.77 (1.63, 1.92)** 0.84 (0.70, 1.01) 
         Network 18 (Southern CA) 0.77 (0.72, 0.83)** 0.42 (0.35, 0.50)** 
Other Variables   
Year of study initiation (Reference: 2005)   
         2006 1.14 (1.08, 1.20)** 0.94 (0.84, 1.05) 
         2007 1.10 (1.04, 1.15)** 0.84 (0.75, 0.94)** 
         2008 1.08 (1.03, 1.14)** 0.80 (0.71, 0.90)** 
         2009 1.12 (1.06, 1.18)** 0.81 (0.72, 0.91)** 
         2010 1.10 (1.05, 1.16)** 0.72 (0.64, 0.81)** 
         2011 1.12 (1.07, 1.18)** 0.66 (0.59, 0.75)** 
         2012 1.14 (1.08, 1.20)** 0.65 (0.58, 0.74)** 
         2013 1.05 (0.99, 1.11) 0.58 (0.51, 0.66)** 
         2014 0.89 (0.85, 0.94)** 0.50 (0.44, 0.57)** 
         2015 0.77 (0.73, 0.81)** 0.47 (0.41, 0.53)** 
         2016 0.71 (0.68, 0.75)** 0.43 (0.38, 0.49)** 
   
Note: * : Significant at P<0.05, ** : Significant at P<0.01 
          Abbreviations: ESRD - End-Stage Renal Disease; WL -Wait List; LDKT - Live Donor Kidney Transplant; CVD - Cardiovascular 
Disease; COPD - Chronic Obstructive Pulmonary Disease; BMI - Body Mass Index; GFR EPI - Glomerular Filtration Rate Epidemiology 
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